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This collaborative statement from the International Society for Holter and Noninvasive 
Electrocardiology/	 Heart	 Rhythm	 Society/	 European	 Heart	 Rhythm	 Association/	
Asia	 Pacific	 Heart	 Rhythm	 Society	 describes	 the	 current	 status	 of	 mobile	 health	
("mHealth")	 technologies	 in	 arrhythmia	management.	 The	 range	 of	 digital	 medical	
tools and heart rhythm disorders that they may be applied to and clinical decisions 
that may be enabled are discussed. The facilitation of comorbidity and lifestyle man-
agement	(increasingly	recognized	to	play	a	role	in	heart	rhythm	disorders)	and	patient	
self-management are novel aspects of mHealth. The promises of predictive analytics 
but also operational challenges in embedding mHealth into routine clinical care are 
explored.
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Centra l  F igure
1  | INTRODUC TION
Document scope and rationale
Digital health is an umbrella term to describe the use of digital in-
formation, data, and communication technologies to collect, share, 
and analyze health information in order to improve patient health, 
education,	 and	 healthcare	 delivery	 (https://www.fcc.gov/gener	al/
five-quest	ions-you-can-ask-your-docto	r-about	-digit	al-healt	h#ab)	
(Turakhia, Desai, & Harrington, 2016).	 This	 concept	 encompasses	
telehealth, electronic health records, implantable device monitor-




supported by mobile devices, such as mobile phones, patient moni-




among health-conscious consumers in recent years and is likely to 
continue rapid expansion and integration into more formalized medi-
cal settings.
mHealth flows intuitively to health professionals in the field of 
arrhythmia management from experience gained through remote 
monitoring	of	cardiovascular	 implantable	electronic	devices	(CIEDs),	
such	as	pacemakers	and	implantable	cardioverter-defibrillators	(ICDs)	
(Varma, Epstein, Irimpen, Schweikert, & Love, 2010).	A	wealth	of	data	
garnered from many studies over the last 10-15 years have confirmed 
the benefits of remote technology-assisted follow-up and established 
it	 as	 standard	 of	 care	 (Varma & Ricci, 2013; Slotwiner et al., 2019).	
However, results of remote monitoring of CIEDs may not be immedi-
ately generalizable to mHealth. For instance, the former is restricted 
to	 those	with	 cardiac	disease	 (largely	 arrhythmias	and	heart	 failure	
(HF)),	that	is,	a	group	already	defined	as	patients.	The	care	pathways	
for CIED remote monitoring are also well defined, with billing and re-
imbursement in place in the United States and many other parts of the 
world. In comparison, mHealth differs: It is widely available in the form 
of consumer products that penetrate most sectors of society, includ-
ing individuals without formal medical diagnoses; it may be applied to 
a wider group of medical conditions; data can be self-monitored rather 
than	assessed	by	healthcare	professionals	(HCPs);	and	reimbursement	
models are not mature. Indeed, some heart rhythm tracking capabil-
ities may be indirectly acquired in products purchased for different 
goals and then subsequently used for self-monitoring. Conversely, in 
the medical space, applications are largely not prescribed by HCPs, 
often lack validation for disease management use cases, and care 
pathways remain varied or poorly defined. Nevertheless, if prop-
erly implemented, the intersection of these two communities opens 
up a broad spectrum of opportunities, extending from population 
F I G U R E  L E G E N D :  mHealth	tools	for	the	individual.	Sensors	can	be	embedded	in	a	variety	of	wearables.	(IoT:	Internet	of	things—
connects	from	any	location	to	hospital	or	cloud;	See	Table	1).
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TA B L E  1   mHealth-based modalities for arrhythmia monitoring
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screening and surveillance for undiagnosed disease to longitudinal 
disease management, and importantly, engaging patients in their own 
cycle of care, allowing much health care to be asynchronous and vir-
tualized. Its value and degree of integration will depend on different 
healthcare	systems	in	different	countries	(Table	1).
mHealth has value only if the acquired information leads to deci-
sions that improve outcome. This requires a clear path of information 
flow and actionability. Moreover, all stakeholders need to be aware 
of	the	logistical	chain	(so	that	everyone	knows	what	to	expect)	and	
responsibilities	 clearly	defined	 (possibly	 including	device	vendors).	
Similarly, actions taken based on the monitored information should 
be transparent to all stakeholders. For example, for a patient who 
records and transmits an irregular heart rhythm via a wearable de-
vice, a designated decision process should be followed to confirm eg 
whether	the	rhythm	is	atrial	fibrillation	(AF)	or	not,	whether	confir-
mation by another diagnostic test is required, how that is arranged, 




rience sets a precedent. Studies that have shown improved outcome 
with telemonitoring succeeded when integrated into a clear logistical 
framework	for	a	specific	use	case	of	disease	management	(e.g.,	IN-
TIME for remote monitoring in patients receiving cardiac resynchro-
nization	therapy,	CardioMEMS)	(Abraham et al., 2011, Hindricks et al., 
2014, Varma & Ricci, 2013).	 Replicating	 this	 with	mHealth	 creates	
challenges for healthcare providers and goes far beyond the tech-
nological capabilities of the monitoring and transmission equipment. 
Implementation will require defined aims and fundamental changes 
to existing workflows and responsibilities. Such changes are always 
difficult.	 Apart	 from	 the	 organizational	 issues	 required	 to	 achieve	
such changes, reimbursement may drive or hinder such changes in 
the	 workplace.	 Awareness	 of	 these	 factors	 has	 been	 heightened	
by	the	SARS-CoV-2	pandemic,	during	which	telemedicine	solutions	
have been advocated to reduce patient contact with healthcare pro-
viders	yet	continue	healthcare	delivery	(Varma et al., 2020).
In view of the rapid technological development and popularity 
of wearable and other mobile devices, and the need for analysis 
and	 planning	 of	 the	mHealth	 infrastructure,	 ISHNE	 (International	
Society	for	Holter	and	Noninvasive	Electrocardiology),	HRS	(Heart	
Rhythm	Society),	EHRA	(European	Heart	Rhythm	Association),	and	
APHRS	 (Asia	 Pacific	Heart	 Rhythm	Society),	 recognized	 the	 need	
for this collaborative statement. The aim of this document is to de-
fine state-of-the-art mHealth technologies and their application in 
arrhythmia management and explore future directions for clinical 
application.	As	such,	the	scope	of	the	document	encompasses	dis-
cussion of the different mHealth technologies currently available or 
in development; the acquisition of health-related data; the applica-
tions of such data, including disease identification and management; 
clinical trials; the patient perspective; and the issues that must be 
addressed in the future to permit useful application of mHealth 
technologies.	Addtionally,	discussion	is	extended	to	mHealth	facil-
itation of those comorbidities increasingly recognized to influence 
arrhythmia	management	(e.g.,	obesity	and	sleep	apnea)	that	are	be-
coming	the	responsibility	of	heart	rhythm	professionals	(Chung et al., 
2020).
R E FE R E N C E S S EC TI O N 1
Abraham,	W.	T.,	Adamson,	P.	B.,	Bourge,	R.	C.,	Aaron,	M.	F.,	Costanzo,	M.	
R.,	Stevenson,	L.	W.,	…	Yadav,	J.	S.	(2011).	Wireless	pulmonary	artery	
haemodynamic	 monitoring	 in	 chronic	 heart	 failure:	 A	 randomised	
controlled trial. Lancet, 377, 658–666. https://doi.org/10.1016/
S0140	-6736(11)60101	-3
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2  | mHE ALTH TECHNOLOGIES
Dedicated applications and sensors, within or adjunctive to mobile 
communication devices, enable users to monitor, collect, and share 
physiologic and health data. Their applications range from diagnos-
tic, decision support, disease management, evaluation of medica-
tion adherence, and for educational and clinical research purposes 
(Figure	1).	They	synergize	naturally	with	arrhythmia	evaluation	and	
extend management to associated comorbidities and lifestyle.
Applications	to	arrhythmias
• Diagnostic
a. Evaluate patients with symptoms suggestive of arrhythmias
b.	 Assess	patients’	response	to	both	pharmacological	and	 inva-




This is the cornerstone diagnostic method, and the choice of 
technique	 and	 time	 frame	 depend	 on	 whether	 symptoms	 (e.g.,	
F I G U R E  1  Application	of	digital	health	
technologies	in	arrhythmias	(Many	of	
these	sectors	are	interconnected).
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palpitations,	 syncope)	 are	 present	 and	 how	 often	 they	 occur	
(Figure	2).	Since	the	XXI	century	has	become	the	era	of	the	AF	epi-
demic, the emphasis has shifted to screen for asymptomatic patients 
at	high	risk	of	developing	AF	or	in	those	with	cryptogenic	stroke,	to	
enable early treatment with the hope of preventing stroke and other 
serious complications. Novel tools expand the time window in which 
information can be gathered and overcome existing limitations with 
traditional methods, that is, intermittent physical examination or 
ECG for the detection of a largely asymptomatic arrhythmia.
•	 Conventional	ambulatory	ECG	devices	with	“continuous”	or	“inter-
mittent”	recording	abilities	(e.g.,	Holter,	mobile	cardiac	telemetry	
(MCT))	 increase	 the	diagnostic	 yield	 for	 suspected	arrhythmias,	
but limitations such as inadequate duration of monitoring, insuf-
ficient	sensitivity	or	specificity	for	AF	detection,	cost,	and	patient	
discomfort and inconvenience remain important implementation 
barriers. Further details on these conventional systems are avail-
able	in	a	prior	expert	consensus	statement	(Steinberg et al., 2017).
•	 Implantable	 loop	 recorders	 (ILRs)	 continuously	 monitor	 cardiac	
rhythm, similar to traditional external loop recorders, but only 
record an ECG shortly before and after activation by either the 
patient or by an automated algorithm. The total monitoring period 
is	limited	only	by	battery	longevity	(ca.	2-5	years).	Newer	devices	
have dedicated algorithms resulting in increased interest in their 
use	for	AF	detection,	especially	after	cryptogenic	stroke.	Several	
approved	ILR	devices	are	available	(Musat, Milstein, & Mittal, 2018, 
Sakhi, Theuns, Szili-Torok, & Yap, 2019, Tomson & Passman, 2015),	and	
several studies have been performed to evaluate the diagnostic ac-
curacy	of	these	devices	(Ciconte et al., 2017, Hindricks et al., 2010, 
Mittal et al., 2016, Nolker et al., 2016, Sanders et al., 2016).	Since	ILRs	
are invasive and costly, some functions may shift to mHealth.
2.2 | New mHealth-based modalities for 
arrhythmia monitoring
These can be divided into technologies that:
•	 Record	ECG	tracings	(single	or	multilead,	in	intermittent	or	contin-
uous	format,	of	various	durations).
• Use non-ECG techniques such as pulse photoplethysmography 
(PPG).
mHealth tools permit indefinite monitoring and widen appli-
cation to a range of conditions and patient populations. There has 
been rapid development and integration of diagnostic sensors into 
consumer devices such as smartwatches, fitness bands, and smart-




F I G U R E  2   mHealth devices for arrhythmia monitoring according to indications. Traditional wearable monitors are used for defined, short 
periods	of	time.	Advantages	are	continuous	monitoring	and	ability	to	use	multiple	leads	that	may	be	important	for	arrhythmia	differentiation.	
These have been used historically for evaluation of palpitations, syncope, and defining QRS morphology. mHealth extends monitoring time 
indefinitely, to be defined by the user, and to the possibility of monitoring other parameters simultaneously with the ECG and linking to 
machine	learning.	Typically,	mHealth	utilizes	single-channel	ECG	or	derived	heart	rate,	and	discontinuous	monitoring.	AF—atrial	fibrillation,	
BP—blood	pressure,	BrS—Brugada	syndrome,	HF—heart	failure,	HR—heart	rate,	ILR—implantable	loop	recorder,	LQT—long	QT.









































































































































































































































































































































































































































































































































































































































































































































































Several stand-alone handheld devices operate without additional 
hardware. These devices with two or three ECG electrodes on either 
side	generate	short,	30	sec	to	1	minute,	single	or	multilead	ECG	re-
cordings. Some of them display ECG tracings on a monitor. Most of 
these devices are equipped with dedicated automatic algorithms for 
detection	of	arrhythmias	and	usually	focus	on	AF.	Recognition	of	AF	
is usually based of the analysis of RR interval irregularity. The devices 
can store ECG tracings, which can be uploaded to a computer for re-
view and are usually available for physicians via web-based platforms. 
Studies across diverse populations have documented the diagnostic 
accuracy	of	handheld	devices	in	detection	of	AF	by	short-term	rhythm	
monitoring	 (Desteghe et al., 2017, Doliwa, Frykman, & Rosenqvist, 
2009, Hendrikx, Rosenqvist, Wester, Sandstrom, & Hornsten, 2014, 
Kaasenbrood  et al., 2016, Poulsen  et al., 2017, Svennberg  et al., 2017, 
Tavernier et al., 2018, Tieleman et al., 2014, Vaes et al., 2014)	(Table	2).
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2.2.1.2 | Wearable patches
Traditional cable/wire-based devices increasingly have been dis-
placed by solutions with electrodes embedded in adhesive patches. 
Commercially	available	patches	can	be	worn	up	to	14	days	(Barrett 
et al., 2014, Turakhia et al., 2013).	Unlike	adhesive	electrodes	for	lead-
based systems, the water-resistant patches are not removed during 
the monitoring period leading to greater wear time, more analyzable 
data, and no lead reversal errors. The cutaneous patch monitors are 
typically single-use and continuously or intermittently record single-
lead electrocardiography. Most have an integrated button to mark 
the	 timing	 of	 symptoms	 on	 the	 recorded	 rhythm	 trace.	 After	 the	
monitoring period, the device is returned to the manufacturer for 
data extraction, analysis by a proprietary algorithm, and further sec-
ondary	analysis	of	potential	arrhythmias	by	medical	 technicians.	A	
diagnostic report is sent to the treating physician. This process may 
be associated with delays of several weeks.
Although	 such	 patches	 only	 record	 a	 single-lead	 ECG,	 a	 high	
agreement	(P<.001)	has	been	demonstrated	compared	to	multi-lead	
Holter	monitors	for	identifying	AF	events	and	estimating	AF	burden	
(Barrett et al., 2014, Rosenberg, Samuel, Thosani, & Zimetbaum, 2013).	
As	the	patch	has	no	external	leads,	it	is	perceived	to	be	more	com-
fortable to wear compared to conventional Holter monitors, with 
94%	of	 the	patients	preferring	 the	patch	over	 the	Holter	 (Barrett 
et al., 2014).	 In	addition	to	the	validation	studies,	the	feasibility	of	
two-week	continuous	monitoring	to	identify	AF	in	an	at-risk	patient	
population has been examined by Turakhia et al. (2015). It has also 
been used successfully to determine the prevalence of subclinical 
AF	in	the	general	population	(Rooney et al., 2019).
Newer patch-based systems add near-real-time analytics and by 
transmitting data continuously to the cloud. This may facilitate more 
rapid data collection and diagnosis. Multiparametric monitoring may 
be	enabled	with	a	patch	worn	for	up	to	3	months	(Stehlik et al., 2020).
2.2.1.3 | Biotextiles
Textile-based systems for ECG monitoring were initially designed to 
ensure patients’ comfort during daily activities and address the needs 
of active patients. These vests and elastic bands adapt easily to pa-
tients’ movements that is particularly important for those perform-
ing physical activities that might be limited by the presence of wires. 
These biomedical devices capture the electrocardiographic signal via 
electrodes integrated into the garment that enables noninvasive ac-
quisition	of	ECG	signal	up	to	30	days.	Single/multilead	selection	(up	
to	full	12-leads)	and	event	activation	are	available.	ECG	signals	can	be	
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stored in memory cards and analyzed afterward as well as transmit-
ted	 in	 real	 time	 via	Bluetooth	 to	 a	 smartphone	 (and	 from	 there	 to	
a	cloud-based	platform),	 along	with	other	 signals	 including	acceler-
ometer	and	global	positioning	system	(GPS).	Other	than	ECG,	some	
devices provide data on activity intensity, respiratory function, and 
sleep	quality.	Automatic	analysis	with	manual	verification	is	possible.	
Several systems for ECG monitoring based on electrodes incorpo-
rated into garments have been introduced into market. Some of them 
acquire signal from chest belts. Maintaining power presents a chal-
lenge. These systems have been tested in athletes, in patients with 
cryptogenic	 stroke,	 and	 in	 those	 with	 pacemaker-detected	 AHRE	
(Eliot, Hamlin, & Lizamore, 2019, Eysenck, Freemantle, & Sulke, 2019, 
Fabregat-Andres et al., 2014, Feito, Moriarty, Mangine, & Monahan, 
2019, Pagola et al., 2018).
The wearable cardioverter-defibrillator transmits 2-channel 
ECG data to an online patient management database allowing for 
remote monitoring of high-risk patients. Recent incorporation of 
heart sound evaluation that may predict HF decompensation will 
be	 tested	 in	 a	 prospective	 trial	 (HEARIT-Reg trial ClinicalTrials.gov 
Identifier: NCT03203629).
2.2.1.4 | Smartphone and smartwatch-based devices
More recently, nonwearable solutions coupled with the smartphone 
have	emerged.	These	devices	(Table	2	and	Varma et al., 2020)	allow	
the	user	to	perform	a	“spot	check”	single-lead	ECG	strip,	usually	of	
up	to	30	seconds	or	longer	by	placing	a	finger	of	each	hand	on	the	
two electrodes, usually located on the phone case or external card 
(Figure	 3).	 The	 ECG	 electrical	 signal	 is	 transmitted	wirelessly	 to	 a	
smartphone with an integrated interpretation app. The tracings can 
be reviewed on the smartphone, electronically stored, or transmit-
ted for review by the user’s provider if desired. These have been 
directed	largely	to	AF.
Automated	 algorithms	 can	 label	 the	 recording	 as	 “Possible	
AF”	 on	 the	basis	 of	 criteria	 for	 the	presence	 and	 absence	of	 a	P	
wave	 and	 the	 irregularity	 of	 the	 RR	 interval;	 “Normal”	 or	 “Sinus	
Rhythm”	and	“Unreadable”	when	the	detector	indicates	there	was	
too much interference for an adequate recording, whether from 
too much movement, or poor contact between the electrodes and 
the	patient’s	skin.	Several	versions	of	the	AliveCor’s	automated	al-
gorithms	have	been	evaluated	(Chan et al., 2016, Chan et al., 2017, 
Desteghe  et al., 2017, Lowres  et al., 2014, Tarakji  et al., 2015),	and	
the device has been tested as a screening tool in at-risk popula-
tions	(Halcox  et al., 2017, Lowres  et al., 2014).	In	Apple	watch,	the	
algorithm is effective when the heart rate is between 50 and 150 
bpm, there are no or very few abnormal beats, and the shape, tim-







requires proper evaluation for every intended use case. There is also 
an accessory band for a smartwatch to allow ECG recording. The sin-
gle-lead	ECG	with	automatic	AF	detection	is	recorded	by	touching	
the band’s integrated sensors that transmit data to a watch applica-
tion. Recently, a new 6-lead case has been developed, allowing for 
30	second	recording	of	all	6	limb	leads	by	touching	each	of	the	three	
electrodes.	Also	the	QT	interval	may	be	derived	from	this	(https://
cardi acrhy thmne ws.com/kardi amobi le-6l-can-be-used-to-measu 
re-qt-durat	ion-in-covid	-19-patie	nts/	(Chung & Guise, 2015, Garabelli 
et al., 2016).	 Information	 is	 limited;	 however,	 on	 how	 parameters	
such	 as	QTc	measured	on	 a	 single-	 (or	 limited	number)	 lead	ECGs	
can reliably substitute for 12-lead ECG information. In one study, 
QT	was	underestimated	by	smartphone	single-lead	ECG	(Koltowski 
et al., 2019).	Preliminary	data	 indicate	ability	for	ST	monitoring	for	
ischemia	(Figure	3,	Section	4.1).
Such devices may be used by clinicians as a point-of-care device 
to obtain an interpretable rhythm strip in place of a 12-lead ECG. In 
addition, patients may use these devices for ad hoc or routine eval-
uation of their rhythm in a home environment. The ECG data can 
be instantaneously transmitted for automated interpretation with 
F I G U R E  3   ECG mobile applications. 
Left—fingertip	recordings;	Right—card	
pressed to the chest.
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the ability of the consumer to request a physician overread for a 
surcharge.
• Limitations
a. Single-lead devices, particularly when used by an active per-
son who may not be recumbent, relaxed, or still, may lead to 
substantial electrical or motion artifact. Noise-free tracing 
may be more difficult for older patients or those with physical 
limitations	(tremor,	stroke,	etc).
b.	 Although	the	 interpretation	algorithms	typically	have	received	
regulatory oversight, these algorithms can frequently misclas-
sify	rhythms,	calling	sinus	rhythm	AF	and	vice	versa,	which	could	
lead to potential harm without confirmation by a clinician. For 
example, in a recent study of a consumer ECG device to detect 
AF,	a	third	of	ECGs	were	unclassifiable	by	the	device	but	could	be	
classified	by	experts	(Bumgarner		et	al.,	2018)	Therefore,	some	






of	 AF	 (Figure	 4)	 (https://suppo	rt.apple.com/en-us/HT208931,	
accessed	January	2,	2020)	(See	Section	6)	.
c. For consumer watches, ECG diagnosis is considered a predi-
agnostic pending medical verification and not designed to be 






Consumer devices such as smartphones and smartwatches require 
accessories and often extra cost for conversion into rhythm monitor-
ing tools. In contrast, the PPG technologies allow for the detection 
of arrhythmias using hardware already present on most consumer 
devices	 (smartwatches	and	fitness	bands)	 through	a	downloadable	
application. PPG is an optical technique that can be used to detect 
AF	by	measuring	and	analyzing	a	peripheral	pulse	waveform.	Using	a	
light source and a photodetector, the pulse waveform can be meas-
ured by detecting changes in the light intensity, which reflects the 
tissue blood volume of a skin surface such as the fingertip, earlobe, 
or	face	(Conroy, Guzman, Hall, Tsouri, & Couderc, 2017, McManus  et al., 
2013).	An	automated	algorithm	can	subsequently	analyze	the	gener-
ated	pulse	waveform	 to	detect	AF.	PPG	avoids	 the	 instability	 and	
motion artifacts of ECG sensors and can be passively and opportun-
istically measured.
This technology has been applied for use with smartphones using 
the phone’s camera to measure a fingertip pulse waveform. Rapid 
irregularly	conducted	AF	may	produce	variable	pulse	pressures	that	
challenge	detection	 (Choi & Shin, 2017).	 The	performance	of	 algo-
rithms interpreting these PPG signals has been proven to be in high 
agreement	with	ECG	rhythm	strips	(McManus  et al., 2013, McManus 
et al., 2016, Proesmans  et al., 2019).	The	smartphone-based	PPG	ap-
plications	have	been	utilized	in	at-risk	population	to	detect	AF	and	
as	a	screening	tool	in	the	general	population	(Verbrugge  et al., 2019)	
(See	Section	6).
The PPG technology has also been incorporated in smart-
watches	 to	measure	heart	 rate	and	 rhythm	 (Dorr  et al., 2019, Guo 
F I G U R E  4  Apple	Watch.
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2019).	Some	have	developed	prototypes	of	a	band	 that	 includes	a	
single-channel ECG, multi-wavelength PPG, and tri-axial accelerom-
etry	recording	simultaneously	at	128	Hz	 (Nemati  et al., 2016),	and	
others use a deep-neural network based on PPG sensors to detect 
AF	 (https://www.mobih	ealth	news.com/conte	nt/study	-apple	-watch	
-paire d-deep-neura l-netwo rk-detec ts-atria l-fibri llati on-97-perce 
nt-accuracy;	 https://mrhyt	hmstu	dy.org).	 If	 PPG	 or	 optical	 sensors	
and detection algorithms can match the performance of ECG-based 
rhythm	assessment,	delivery	of	AF	care	may	be	expected	to	change	






Lei, & Wang, 2017).	Automated	BP	monitors	have	been	used	for	op-
portunistic	AF	detection.	Studies	have	shown	that	six	devices	from	
two manufacturers were reliable with sensitivities and specificities 
greater	than	85%	(Kane, Blake, McArdle, Langley, & Sims, 2016).	These	
studies	suggested	that	BP	devices	with	embedded	algorithms	for	de-
tecting	arrhythmias	show	promise	as	screening	tools	for	AF,	compar-
ing favorably with manual pulse palpation. Such capability could be 
added	to	continuous	BP	recording	devices	(Kario, 2016).	One	device	
identifies	possible	AF	when	at	least	two	of	three	consecutive	meas-
urements show pulse irregularity. Several studies addressed the di-
agnostic	accuracy	(Chan et al., 2017, Chen, Lei, & Wang, 2017, Gandolfo, 
Balestrino, Bruno, Finocchi, & Reale, 2015, Kearley  et al., 2014, Marazzi 
et al., 2012, Stergiou, Karpettas, Protogerou, Nasothimiou, & Kyriakidis, 
2009, Wiesel, Fitzig, Herschman, & Messineo, 2009, Wiesel, Arbesfeld, & 
Schechter, 2014) and the feasibility of this device as a screening tool 
(Chan  et al., 2017, Omboni & Verberk, 2016, Wiesel & Salomone, 2017).
The following have undergone preliminary study:
2.2.2.3 | Mechanocardiography
Mechanocardiography uses accelerometers and gyroscopes to sense 
the mechanical activity of the heart. The accuracy of this technology 
to	detect	AF	using	a	smartphone’s	built-in	accelerometer	and	gyro-
scope	 sensors	was	 assessed	 in	 a	proof	of	 concept	 study	 (Jaakkola 
et al., 2018).	A	smartwatch	(Sony	Experia)	was	placed	on	the	chest	
in supine patients to detect micro movements of the chest. Possibly, 
carrying this device in a pocket may have utility but is likely to be 
confounded	by	movement	(e.g.,	walking)	artifacts.
2.2.2.4 | Contactless video plethysmography
Noncontact video monitoring of respiration and heart rate have been 
developed	less	than	15	years	ago	(Takano  & Ohta, 2007, Verkruysse, 
Svaasand, & Nelson, 2008). In 2014, a pioneering article described the 
concept	of	contactless	video-based	detection	of	AF	(Couderc et al., 
2015).	Deep	learning	of	a	video	of	a	person’s	face	can	identify	AF	by	
examining	irregularity	of	pulsatile	facial	perfusion	(Yan et al., 2018).	It	
is a monitoring technique extracting the photoplethysmographic-like 
signals	 from	a	 standard	digital	RGB	video	 recording	of	 the	human	
skin and specifically of an individual’s face. The videoplethysmo-
graphic signal describes the absorption peak of ambient light by 
the hemoglobin from the facial skin. Several studies have been per-
formed to develop a method that is sensitive enough to detect each 
cardiac pulse and provide insights into variability on pulse on a beat-
to-beat basis. The HealthKam works using HUE color space from 
video	cameras	(Dautov, Savur, & Tsouri, 2018, Tsouri & Li, 2015)	and	
can easily be integrated to any portable computer device with a cam-
era	(smartphone,	tablet,	etc.).	By	using	mobile	devices	with	cameras,	
the deployment of the technology is easy and scalable since it does 
not require the use and distribution of any physical devices. Such a 
system	may	change	the	approach	to	AF	screening,	which	currently	is	
only	1	patient	at	a	time.	High-throughput	AF	detection	from	multiple	
patients concurrently using a single digital camera and a pretrained 
deep	convolutional	neural	network	 (DCNN)	was	 feasible	 in	a	pilot	
study	(Yan  et al., 2020).
Limitations
One requirement for these technologies is steady focus: Thus moving 
subjects present a challenge. It is important to avoid recording, send-
ing, or communicating any video of the patient thus protecting privacy 
and dignity. Video-based technologies in telemedicine have raised a 
new set of societal and ethical concerns that are being continuously 
re-evaluated such as during the COVID-19 pandemic. Issues regard-
ing privacy, confidentiality, and legal and ethical obligation to treat are 
crucial factors to be considered when these technologies are deployed 
at	larger	scale	(Turakhia 2020).
2.2.2.5 | Smart speakers
There are preliminary reports on using commodity smart devices 
to identify agonal breathing (Chan, Rea, Gollakota, & Sunshine, 2019, 
Wang, Sunshine, & Gollakota, 2019). Identification of abnormal heart 
rate patterns may be made possible by converting smart speakers 
into a sonar device with emission of in-audible frequencies sound 
waves and receiving them to detect motion. These are not in con-
sumer domain but potentially have wide scalability.
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3  | mHE ALTH APPLIC ATIONS FOR 
ARRHY THMIA S
Typically, most patients with palpitations and dizziness are evaluated 
using	 the	 various	 technologies	 reviewed	 in	 Section	 2.1	 (Steinberg 
et al., 2017). Devices capable of recording at least one ECG lead allow 
the interpreting clinician to distinguish between wide- and narrow-
complex rhythms, bradycardia, and tachycardia, and thus distinguish 
between the various causative rhythms. Smart devices may be use-
ful	in	pediatric	patients	(Gropler, Dalal, Van Hare, & Silva, 2018).
3.1 | Atrial fibrillation
The disease is often intermittent and asymptomatic, which may delay 
diagnosis (McCabe, Chamberlain, Rhudy, & DeVon, 2015, Strickberger, 
Ip, Saksena, Curry, Bahnson, & Ziegler, 2005, Verma et al., 2013),	 lead	to	
incorrect	estimation	of	AF	burden	(Boriani et al., 2015, Garimella et al., 
2015),	and	pose	management	challenges	to	healthcare	services,	thereby	
exposing	the	patient	to	the	consequences	of	untreated	AF.	New	digital	
health and sensor technologies have the potential for early identification 
of	AF,	opening	up	opportunities	for	screening,	which	then	can	be	tied	to	
evidence-based management. These may be directed to several broad 
groups: for screening the general population or managing the already di-
agnosed, for following responses to treatment, and increasingly to man-
aging	comorbidities	and	lifestyle	modification	(See	Section	4)	(Figure	5).	
mHealth mechanisms may facilitate understanding the relation between 
AF	burden,	its	progression,	and	cardiovascular	risk	(Wong et al., 2018).
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TA B L E  3   Selected screening studies for atrial fibrillation using newer technologies
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3.1.1 | Undiagnosed atrial fibrillation identification
Classical epidemiological data point to the notion that early identifica-
tion	of	AF	has	the	potential	to	improve	morbidity	and	possibly	mortality.	
(1)	AF	is	associated	with	a	5-fold	increased	risk	of	stroke	(Wolf, Abbott, 
& Kannel, 1991)	 and	doubled	mortality	 (Kirchhof et al., 2016);	 (2)	 The	
prevalence	of	undiagnosed	AF	is	at	least	1.5%	for	patients	> 65 years 
(Orchard et al., 2018);	(3)	In	about	a	quarter	of	all	AF-related	strokes,	the	
stroke	is	the	first	manifestation	of	the	arrhythmia	(Friberg  et al., 2014)	
while	other	AF	patients	present	first	with	congestive	HF;	(4)	Stroke	risk	
is	 independent	 of	 symptoms	 (Xiong, Prioietti, Senoo, & Lip, 2015);	 (5)	
Diagnosis often requires repeated or prolonged ECG monitoring; and 
(6)	Oral	anticoagulants	(OACs)	are	highly	effective	in	reducing	the	risk	
of cardioembolic stroke, mortality, and possibly dementia in the setting 
of	AF	(Ding & Qiu, 2018, Friberg & Rosenqvist, 2018).
Atrial	fibrillation	identification	depends	on	factors	having	to	do	
with	the	arrhythmia	itself,	that	is	the	combination	of	AF	prevalence	
and	density	(Charitos et al., 2012),	and	factors	associated	with	detec-
tion such as the frequency and duration of monitoring and diagnostic 
test	performance	(Ramkumar et al., 2018). Several studies including 
patients with variable stroke risk factors have used mHealth tech-
nologies	to	identify	undiagnosed	AF	(Tables	2	and	3),	but	these	may	
require gold-standard ECG confirmation.
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pretest	probability	of	AF	 in	a	given	population	 (e.g.,	 those	with	an	
established	diagnosis	or	one	or	more	risk	factors).	This	is	especially	
relevant	to	“healthy	consumers.”	Many	technologies	to	identify	AF	
are readily available directly to those without defined disease and 
are not deployed as individual or public health interventions. Rather, 
consumers who possess these technologies, such as smartwatches 
or smartphone-connected ECG recorders, opt into the use of these 
technologies.	 Therefore,	 consumer-driven	 AF	 identification	 is	 not	
the	same	as	healthcare-initiated	AF	screening.	AF	identification	by	
these	devices	requires	confirmation,	since	these	AF	screening	tools	
have	 variable	 specificity	 (Table	 2),	 raising	 the	 potential	 of	 a	 high	
false-positive rate in a low prevalence population, and risks of un-
necessary treatment.
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There have been almost 500 studies assessing accuracy of 
mHealth	devices	for	AF	detection,	as	described	in	recent	systematic	
reviews	 (Giebel & Gissel, 2019, Lowres et al., 2019, O’Sullivan  et al., 
2020).	 Their	 capabilities	 varied	 according	 to	 technologies	 utilized,	




stroke and death has been conducted as yet.
Although	an	incidental	diagnosis	of	AF	seems	to	be	associated	with	
increased	 risk	 of	 stroke	 and	 protection	 by	 OAC	 therapy	 (Freedman, 
Potpara, & Lip, 2016, Martinez, Katholing, & Freedman, 2014, Tsivgoulis 
et al., 2019),	 clinical	 trials	 to	 determine	 any	 benefit	 for	 opportunis-
tically	 detected	AF	 have	 not	 yet	 been	 completed	 but	 are	 underway	









aged	≥65	years	(Freedman  et al., 2017, January  et al., 2019, Kirchhof 
et al., 2016).	On	the	other	hand,	the	U.	S.	Preventive	Services	Task	
Force	has	presently	given	an	“insufficient”	recommendation	for	sys-
tematic	screening	for	AF	with	electrocardiograms	(Jonas et al., 2018).
3.1.2 | Targeted identification in high-risk individuals
Cryptogenic stroke/TIA
Up	to	one-third	of	ischemic	strokes	is	attributed	to	AF	mediated	em-
bolism	 to	 the	brain	 (Hannon et al., 2010).	 Further,	 the	 risk	of	 recur-
rent	thromboembolism	is	high	if	AF	is	left	undetected	and	untreated	
(Furie et al., 2012, Kolominsky-Rabas et al., 2001).	 Hence,	 prolonged	
monitoring	for	AF	poststroke	has	been	recommended	in	recent	guide-
lines	 (January et al., 2019, Kirchhof et al., 2016, Schnabel et al., 2019).	
Detection	of	AF	poststroke	depends	not	only	on	the	monitoring	de-
vice used and the duration of the monitoring period, but also on stroke 
type	and	patient	selection;	thus,	the	results	of	AF	detection	have	been	
heterogenous (Kishore et al., 2014, Sanna et al., 2014, Zungsontiporn 
& Link, 2018).	A	meta-analysis	 showed	 that	 a	 stepwise	 approach	 to	
AF	detection	in	poststroke	patients	led	to	AF	detection	in	23.7%	of	
patients	(Sposato et al., 2015),	while	a	combined	analysis	of	two	ran-
domized and two observational studies showed a 55% reduction in 
recurrent	 stroke	 following	 prolonged	 cardiac	 monitoring	 (Tsivgoulis 
et al., 2019).	However,	the	optimal	AF	duration	threshold	for	 initiat-
ing anticoagulation is currently unknown and may be lower in a post-
stroke population compared to those with fewer cardiovascular risk 
factors	(Kaplan et al., 2019).
The	 risk	 of	 undiagnosed	 AF	 and	 other	 sources	 of	 thrombi	
has been considered high in embolic strokes of unknown source 
(ESUS),	prompting	studies	 that	evaluated	whether	empiric	NOAC	
therapy is more effective than antiplatelet therapy without a re-
quirement	of	AF	detection.	Two	of	these	studies,	NAVIGATE	ESUS	
F I G U R E  5  mHealth	and	AF.	Applications	include	screening	for	AF	in	general	or	high-risk	populations,	managing	comorbidities	and	
lifestyles	important	for	prevention	and	control,	as	well	as	managing	treatment	of	known	AF.	AF—atrial	fibrillation,	DM—diabetes,	HTN—
hypertension,	NSR—normal	sinus	rhythm.
     |  19 of 54VARMA et Al.







These	 findings	 underscore	 the	 need	 for	 AF	 detection	 prior	
to	 initiation	 of	OAC	 therapy	 in	 patients	with	 cryptogenic	 stroke,	
ESUS, or ischemic stroke of known origin, and mHealth devices 
can	 ease	 the	 process	 of	 detection	 (Zungsontiporn & Link, 2018).	
The	threshold	of	AF	burden	may	very	well	differ	 in	patients	who	
have had a suspected cardioembolic event and those who have not 
(Kaplan et al., 2019).
Other high-risk individuals
The	key	to	making	AF	identification	feasible,	efficient	and	clinically	
valuable is the selection of patients with an increased likelihood of 
harboring	undiagnosed	AF,	rather	than	general	screening	in	unse-




intermittent or nonpersistent arrhythmias; however, it is likely that 
frequent sampling would be necessary to capture infrequent par-
oxysmal	AF	 and	 even	daily	 “snapshot”	 ECG	monitoring	may	miss	
half	of	AF	episodes	(Charitos et al., 2012, Yano et al., 2016).	AF	bur-
den, increasingly recognized as a powerful independent predictor 
of	 stroke	 (Chen et al., 2018), though accurately measured by im-
planted	devices	(Varma, Stambler, & Chun, 2005),	cannot	be	readily	
calculated from intermittent ECG data. The use of smartwatches 
with passive intermittent surveillance using PPG monitoring plus 
ECG confirmation may be a more effective screening tool and is 
currently	being	evaluated	 (Heartline study https://www.heart line.
com).
Formal screening with mHealth ECG recordings has yielded 
meaningful	 incidences	of	newly	diagnosed	AF,	 statistically	 greater	
than	 if	diagnosis	 relied	only	on	the	office	ECG	(Table	3).	The	yield	
generally is enhanced by the presence of risk factors, such as older 
age	and	higher	CHA2DS2-VASc	scores.	Several	studies	(Chan & Choy, 




up to 7.4% when additional risk factors beyond age were required 
(Engdahl, Andersson, Mirskaya, & Rosenqvist, 2013, Gudmundsdottir 
et al., 2020, Svennberg et al., 2015).	Lowres et al in a patient level me-
ta-nalysis	found	that	new	AF	detection	rate	increased	progressively	
with	age	from	0.34%	for	<60	years	to	2.73%	≥85	years.	Importantly,	
the	 number	 of	 subjects	 needed	 to	 screen	 to	 discover	AF	meeting	
indications for anticoagulation was 1089 for subjects <60 years but 
83	≥65	years.
3.1.3 | Diagnostics in people with established atrial 
fibrillation
mHealth has important implications for the care of those already 
diagnosed	with	AF.	Several	key	characteristics	of	AF	can	be	meas-
ured with long-term continuous or near-continuous monitoring, and 
the information gained may provide valuable information for patient 
management.
Furthermore, while several studies succeeded in establishing the 
sensitivity	and	specificity	of	novel	devices	for	the	detection	of	AF,	no	
study to date has yet evaluated the utility of an mHealth intervention 
in	 affecting	 clinical	 outcomes.	 The	 iPhone	Helping	 Evaluate	Atrial	
Fibrillation	Rhythm	 through	Technology	 (iHEART),	 a	 single-center,	
prospective, randomized controlled trial, and the Heartline study 




Current guidelines for anticoagulation are based principally on the 
presence	of	risk	factors	and	a	diagnosis	of	clinical	AF,	regardless	of	AF	
duration,	symptomatology,	or	burden	(January et al., 2019).	This	ap-
plies	even	if	the	AF	has	been	quiescent	for	long	periods	or	eliminated	
altogether as the result of rhythm control interventions including an-
tiarrhythmic	drugs,	ablation,	or	risk	factor	modification	(January et al., 
2019).	However,	there	is	increasing	recognition	that	AF	burden	mat-
ters; for example, paroxysmal events have less thromboembolic risk 
than	persistent	AF	 (Chen et al., 2018).	This	understanding	has	been	
extended	during	continuous	monitoring	from	CIEDs	which	depict	AF	
with	high	granularity,	and	first	advanced	the	metrics	of	“AF	days”	and	
burden	 in	 terms	 of	 cumulative	 load	 (hours/day)	 and	 concentration	




tion, and density. Retrieved data provide an insight into natural his-
tory	and	associated	sequelae	(Healey et al., 2012, Kaplan et al., 2019, 
Van Gelder et al., 2017, Varma, Stambler, & Chun, 2005).	This	led	to	oral	
anticoagulation intervention trials to determine the ability to reduce 
stroke	on	 the	basis	 of	AF	duration	 (Lopes et al., 2017, Martin et al., 
2015).	These	suggest	that	a	threshold	exists	below	which	the	risk	of	
thromboembolic stroke is low and risk–benefit ratio may not justify 
chronic administration of oral anticoagulants. For instance, CIED data 
indicate	that	short	subclinical	AF	events	have	lesser	risk	than	more	
prolonged	(and	therefore	more	likely	to	be	symptomatic)	events	(Al-
Turki, Marafi, Russo, Proietti, & Essebag, 2019).	Device-detected,	“sub-
clinical”	atrial	high-rate	episodes	(AHRE)	lasting	6	minutes	to	24	hours	
are associated with increased stroke risk, but the absolute risk is con-
siderably	 lower	 than	 expected	 based	 on	 risk	 factors	 alone	 (Glotzer 
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et al., 2003, Healey et al., 2012, van Gelder et al., 2017). Whether these 
require anticoagulation in high-risk individuals is the subject of ongo-
ing	 studies	 (Kirchoff et al., 2017, Lopes et al., 2017, van Gelder et al., 
2017).	 Importantly,	very	short	AF	episodes	(episodes	in	which	both	
the	onset	and	offset	of	AT/AF	were	present	within	a	single	EGM	re-




tients without indication for implantable devices. mHealth extends 
AF	 screening	 to	 younger	 patients	 without	 cardiovascular	 disease	
and	thromboembolic	potential	may	be	low.	Those	with	high	AF	bur-
den	(defined	by	≥	11.4%;	mean	duration	11.7	hours)	detected	on	a	
14-day patch monitor had an increased thromboembolic event rate 
compared	 to	 those	with	 lower	AF	burdens	 (Go et al., 2018).	There	
remains	significant	treatment	variation	in	use	of	OAC,	especially	for	
device-detected	AF	(Perino et al., 2019).	This	may	be	due	to	a	large	
clinical uncertainty regarding the optimal cutpoint, even though ob-
servational	 data	 indicate	 that	OAC	 is	 associated	with	 a	decreased	
risk of stroke for episodes > 24 hours and possibly for episodes 6-24 
hours	(Perino et al., 2019).
Currently, there are no prospectively validated cutpoints or risk 
models	that	incorporate	AF	burden	into	decision-making	for	stroke	
prevention therapies.
Key knowledge gap: 
•	 Identify	 characteristics	 (duration,	 episode	 number/	 density)	
and risk factors that justify anticoagulation for mHealth detected 
AF.




some	antiarrhythmic	drugs	(Garebelli et al., 2016),	and	discussion	




shown	to	reduce	AF	burden	(Congrete et al., 2018, Kanagala et al., 
2003, Pathak et al., 2015, Voskoboinik et al., 2020).
• Rate	While	the	primary	goal	of	rate	control	is	to	minimize	AF-related	
symptoms, prolonged tachycardia can result in effort intolerance 
and/or tachycardia-mediated cardiomyopathy while excessively low 
heart rate targets may increase the risk of bradyarrhythmias that 
result in symptoms and device implantation. The European Society 
of	Cardiology	recommends	lenient	resting	heart	rate	targets	(<100-
110),	whereas	the	ACC/AHA/HRS	guidelines	recommend	a	target	
rate of <80 bpm. Often these targets are tailored to the individ-
ual patient based on symptoms and presence or propensity for HF. 
mHealth technologies can be used to assess ventricular rates during 
AF	over	long	time	periods	and	evaluate	the	effects	of	rate-control	




The use of mHealth technology to diagnose ventricular arrhyth-
mias	 lags	behind	 its	application	 to	AF	 (See	section	3.1).	Detection	
of	 symptomatic	 VT	 has	 been	 reported	 using	 the	AliveCor	 cardiac	
monitor	(AliveCor,	San	Francisco,	USA)	and	SmartWatch	(Ringwald, 
Crich, & Beysard, 2019, Waks, Fein, & Das, 2015).	Sophisticated	auto-
mated analysis of a 2-minute PPG recording by the camera of a com-
mercially	 available	 smartphone	 (iPhone	 4S,	 Apple)	 can	 distinguish	
between	AF,	PACs,	and	PVCs	from	sinus	rhythm,	with	a	sensitivity	
of	0.733	and	specificity	of	0.976	for	PVCs	(Chong, Esa, McManus, & 
Chon, 2015, McManus et al., 2016).	PVCs	may	challenge	to	PPG-based	
systems,	as	many	PVCs	are	nonperfusing	(Billet et al., 2019).	An	ECG	




Syncope presents unique challenges for mHealth applications. While 
prolonged ambulatory monitoring using medical-grade devices 
(wearable	and	implantable)	has	been	the	mainstay	of	cardiac	rhythm	
diagnosis during episodes of syncope, user-activated systems must 
either	 be	 activated	 by	 the	 patient	 during	 prodromal	 symptoms	 (if	
present	and	time	permits)	in	anticipation	of	syncope,	or	else	incor-
porate	 loop	 recording	 to	 allow	 postsyncope	 activation	 (Steinberg 
et al., 2017).	This	 capability	 is	not	 incorporated	 in	 currently	popu-
lar consumer-grade wearable devices. However, a randomized con-
trolled	trial	of	AliveCor	versus	usual	care	in	participants	presenting	
with palpitations or presyncope showed a faster and increased rate 
of detection of symptomatic arrhythmias in the intervention group, 
suggesting that at least in presyncope, patient-activated rhythm de-
tection using a commercially available mHealth device is productive 
(Reed et al., 2019).	Rhythms	reported	by	devices	that	rely	on	heart	
rates will likely require validation with a medical-grade system to 
provide an ECG tracing during an event to allow determination of 
the causative rhythm.
There is a significant overlap between transient loss of con-
sciousness and mechanical falls due to orthostatic intolerance, 
neurologic, or orthopedic problems. This is particularly disabling in 
elderly	subjects	and	often	unwitnessed	(Davis et al., 2010, Heinrich, 
Rapp, Rissmann, Becker, & Konig, 2010).	Mobile	applications	that	com-
bine analysis of heart rate monitoring together with fall detection, 
GPS positioning, video recording with display of patients’ surround-
ings, and the capability to send alerts either triggered by patients in 
case of symptoms or automatically in case of detected falls, may be 
useful.




for cardiac arrest has consistently been associated with improved 
survival, pre-emptive identification of at-risk persons, detection of 
cardiac arrests, alerting of nearby lay and professional first respond-
ers, and coaching or quality assurance in the performance of car-
diopulmonary	resuscitation	(CPR)	are	ideally	suited	to	the	mHealth	
paradigm in societies where mobile smartphones are ubiquitous.
Prediction
It is possible that mHealth devices which continuously monitor heart 
rhythm and other physiologic data may be able to better predict im-
pending	SCA,	even	using	measures	which	have	not	shown	sufficient	
specificity or sensitivity when measured intermittently, such as heart 
rate	variability	(Lee, Shin, Seo, Nam, & Joo, 2016).	However,	such	con-
tinuous monitoring is present already in CIEDs and has not yet proven 
to	be	sufficiently	predictive	to	be	clinically	useful	(Au-Yeung, Reinhall, 
Bardy, & Brunton, 2018).	Therefore,	the	prediction	of	SCA	by	mHealth	
devices, while a tantalizing prospect, remains to be realized.
Notification and reaction
Once cardiac arrest occurs, rapid identification is essential to trigger 
a response by emergency responders. Wearable devices that com-
bine physiologic monitoring, GPS, and a method of communication 
with emergency services such as cellular service are well positioned 
to provide almost instantaneous alert as well as location informa-
tion	 (Kwon, Lee, Lee, Lee, & Park, 2018, Praveen Kumar, Amgoth, & 
Annavarapu, 2019).	An	early	device	using	a	piezoelectric	sensor	to	
detect the pulse was capable of transmitting an alert to emergency 
medical system or other responders when a pulse was not detected 
and	the	watch	(and	thus	the	wearer)	was	still	 (Rickard et al., 2011).	
Preliminary reports indicate that smart speakers in commodity 
smart devices may be able to identify agonal breath patterns for 
sudden cardiac death detection (Chan, Rea, Gollakota, & Sunshine, 
2019). Widespread diffusion of such technology to patients at el-
evated	risk	of	SCA	will	be	necessary	before	any	potential	benefits	
can be tested.
The ubiquity of mobile phones in society leads to more rapid 
notification of emergency services, and the possibility of a dis-
patcher gathering information from a bystander at the patient’s 
side and delivering instructions on care, such as CPR. This was 
associated with improved outcomes for a variety of emergen-
cies	 (Wu et al., 2012).	 Notification	 of	 lay	 first	 responders	 in	 the	
vicinity of a cardiac arrest is also feasible with current technol-
ogy.	A	blinded,	randomized	trial	conducted	in	Stockholm,	Sweden,	
demonstrated that such a system improved the rate of bystander 
CPR	(Ringh  et al., 2015).	However,	almost	10,000	volunteers	were	
recruited over approximately 18 months, during which 667 activa-
tions occurred, emphasizing the large resources needed and the 
low rate of utilization of trained volunteers, even when alerted by 
mobile phone.
Whether a trained or novice bystander responds, mobile de-
vices	may	be	further	useful	to	provide	voice	(or	video)	instructions	
from a dispatcher or from the device itself. Studies of prerecorded 
audio, live video, and animation-based instruction have shown im-
provements	in	some	aspects	of	CPR	delivery	and	AED	use,	although	
technology	continues	 to	evolve	 (Bolle, Scholl, & Gilbert, 2009, Choa 
et al., 2008, Merchant et al., 2010, You, Park, Chung & Park, 2008).	One	
limitation is that as such apps are unregulated, many do not convey 
current basic life support algorithms and may have poor usability 
(Kalz et al., 2014).	In	addition,	delay	in	commencing	CPR	and	in	calling	
emergency services due to distraction of the rescuer by using an app 
is	a	concern	(Paal et al., 2012).
Automated	 external	 defibrillator	 (AED)	 use	 in	 cardiac	 ar-
rest	 is	 associated	 with	 improved	 survival,	 but	 AED	 use	 remains	
low	 (Weisfeldt et al., 2010).	 Mobile	 devices	 have	 the	 potential	
to	 increase	 this	 by	 assisting	with	 the	 retrieval	 and	use	of	AEDs.	
Multiple	apps	have	been	created	to	locate	AEDs	in	the	vicinity	of	
the	user,	 although	with	mixed	 results	 in	 simulations	 (Sakai et al., 
2011, Hatakeyama et al., 2018, Neves Briard et al., 2019).	Barriers	
include	the	accuracy	of	AED	location	databases,	size	of	the	user	
base, app interface, and the availability of multiple apps instead of 
a	single	validated	regional,	national,	or	international	standard.	An	
emerging approach to circumvent these limitations is the dispatch 
of	an	AED	via	a	drone	to	the	location	of	the	cardiac	arrest,	which	is	
expected to reduce time to defibrillation, especially in rural areas 
(Boutilier et al., 2017).	Feasibility	has	been	demonstrated	(Claesson 
et al., 2017).
Clinical trial
The complete chain from activation of citizen responders was tested 
in	the	Heartrunner	trial	(Andelius et al., 2020)	in	a	region	of	almost	2	
million inhabitants. Results showed that citizen responders arrived 
before emergency services 42% of out of hospital cardiac arrests, 
accompanied by a threefold increase in bystander defibrillation with 
a	trend	to	improved	30-day	survival.	Results	were	more	pronounced	
when emergency arrival times were longer, for example, in rural 
areas.
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4  | COMORBIDITIES
A	 large	 proportion	 of	 arrhythmias	 are	 influenced	 by	 coexisting	
conditions. Their management may directly affect arrhythmia re-
currence and outcome. Thus, lifestyle modifications and manage-
ment	of	comorbid	conditions	(Figure	5)	is	becoming	an	objective	of	
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arrhythmia	management	 (Chung et al., 2020)	 and	 received	 a	Class	
1	recommendation	in	most	recent	guidelines	(January et al., 2019). 




dromes may reduce infarct territory and ventricular arrhythmias, 
thereby	improving	outcome.	AF	after	myocardial	infarction	worsens	
prognosis	(Pizzetti  et al., 2001).
At home
ST segment monitoring technology embedded in conventionally indi-
cated ICDs when tested in a randomized cross-over study suggested 
a reduction in the time from the onset of ischemia to presentation 
to	hospital	 (Gibson et al., 2019, Holmes et al., 2019).	The	AngelMed	
Guardian	system	(Angel	Medical	Systems,	Eatontown,	New	Jersey)	
is approved for use in the United States for patients with prior acute 
coronary	syndrome	(ACS)	who	remain	at	high	risk	for	recurrent	ACS.	
For lower-risk patients, mHealth may improve symptom recognition 
and	 earlier	 presentation,	 that	 is,	 “symptom-to-door	 time”	 (Moser 
et al., 2006).
Wearable devices that continuously monitor physiologic data 
promise detection, and possibly pre-emption, of the early stages of 
MI,	by	alerting	patient	and/or	healthcare	team	early.	A	noninvasive	
device consisting of a three-lead ECG linked wirelessly to a dedi-
cated	mobile	device	has	 recently	been	described	 (Van Heuverswyn 
et al., 2019).	Three	lead	ECG	tracings	(as	well	as	derived	augmented	
limb	 leads)	 can	 be	 recorded	 with	 commercially	 available	 smart-
watches	(Avila, 2019).	Limitations	of	this	approach	are	the	need	for	
the patient or a bystander to possess the device or app, and be famil-
iar with its use, before the onset of symptoms.
An	 emerging	 technology	 (www.heart	beam.com)	 uses	 a	 credit	
card	sized	device	that	is	pressed	against	the	user's	chest	(Figure	3).	
It	collects	ECG	signals	using	a	novel	3D	vector	approach.	The	signals	
are sent to the cloud, where they are analyzed and compared to the 
patient’s	 asymptomatic	 baseline	 reading.	 A	 proprietary	 algorithm	
combines the signal analysis with the patient’s history and reported 
symptoms. This information, along with a diagnostic recommen-
dation and ECG waveforms, is sent to the patient’s physician, who 
makes a final determination and informs the patient This system is 
used by patients in the telehealth setting to assess whether chest 
pain is the result of an myocardial infarction.
Emergency teams
The next step of patient care involved transmission of ECGs by 
emergency responders in the field to hospitals for review and tri-
age and was shown to result in shorter door-to-balloon time, lower 
peak troponin and creatine phosphokinase levels, higher postinfarc-
tion left ventricular ejection fraction, and shorter length of stay 
compared with control patients whose ECGs were not transmitted 
(Clemmensen, Loumann-Nielson, & Sejersten, 2010, Sanchez-Ross et al., 
2011).	This	paradigm	has	now	been	widely	implemented.	Technical	
factors, such as transmission failure and lack of network coverage, 
are the main impediments to adoption of such systems.
Posthospital care
This is often confusing for patients, who often exhibit a poor un-
derstanding of their medications, follow-up procedures, and fu-
ture	appointments	 (Horwitz et al., 2013; Ziaeian, Araujo, Van Ness, 
& Horwitz, 2012).	 This	 contributes	 to	 frequent	 hospital	 readmis-
sions. Mobile technologies may enable individualized contact 
between patients and healthcare providers. Phone calls led to a 
modest improvement in medication adherence in patients with 
F I G U R E  6   Digital applications can 
integrate patient relayed information 
of sensor and clinical information with 
automatic remote analysis, but also permit 
patients to receive advice and treatment 
adjustments from physicians directly.
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coronary artery disease in one large randomized controlled trial 
(Vollmer et al., 2014).	Text	messaging	was	shown	to	increase	medi-
cation	adherence	and	 improved	cardiovascular	 risk	 factors	 (Chow 
et al., 2015; Unal, Giakoumidakis, Khan, & Patelarou, 2018).	Available	
evidence is limited by short-term follow-up and self-reported ad-
herence	 (Shariful Islam et al., 2019).	 Success	may	 depend	 on	 per-
sonalized messages with tailored advice, the ability to respond to 
texts, timing messages to coincide with medication doses, higher 
frequency of messages, and the use of additional apps or websites 
(Park, Beatty, Stafford, & Whooley, 2016).	 Interoperability	with	 the	
EMR may facilitate this approach.
Cardiac rehabilitation
This was shown to improve health outcomes among patients with heart 
disease, but is underutilized. The Million Hearts Cardiac Rehabilitation 
Collaborative	 aims	 to	 increase	 participation	 rates	 to	 ≥70%	 by	 2022	
(Ritchey et al., 2020).	Mobile	apps	and	linked	sensors	to	measure	heart	
rate, respiration rate, and exercise parameters may overcome tradi-
tional limitations of availability, cost, and convenience and be more ac-
ceptable	to	some	patients	(Zwisler et al., 2016).	A	randomized	controlled	
trial center-based and mobile rehabilitation found improved uptake, 
adherence, and completion with home-based cardiac rehabilitation in 
postinfarction	patients	(Varnfield et al., 2014)	(See	also	4.2.2.)
4.2 | Heart failure
Heart failure is widely prevalent, costly to manage, and degrades pa-
tient	outcomes	(Benjamin et al., 2017, Albert & Estep, 2019).	HF	may	
trigger	AF	and	ventricular	arrhythmias.	Conversely,	AF	may	precipi-
tate HF. Remote monitoring of, for example, dietary and medication 
adherence	(See	Section	4.6.2),	detection	of	arrhythmias	(See	Section	
3),	 intercurrent	 ischemia	 (See	 Section	 4.1),	 orthopnea,	 changes	 in	
heart	rate,	activity,	and	sleep	(See	Section	4.5)	may	enable	remote	
adjustment of management to reduce emergency department visits 
and unplanned HF-related hospitalizations. If scalable, remote moni-
toring coupled with mobile communication could prove to reduce 
costs associated with HF.
Despite promise, most large, multicenter randomized trials failed 
to demonstrate improved outcomes of remote monitoring in HF pa-
tients	 (Table	4)	 (Boyne et al., 2012, Chaudhry  et al., 2010, Dickinson 
et al., 2018, Koehler et al., 2011, Ong et al., 2016, Takahashi et al., 2012).	
Combination algorithms based on multiple parameters may be valu-
able	 (Ono & Varma, 2017).	One	 trial	 stands	 out.	 The	 TIM-HF2	 trial	
TA B L E  4  Randomized	trials	with	neutral	results	based	on	external-device	remote	patient	monitoring	(RPM)
Study name
Sample 
size Study design and tested modality Potential explanantion for lack of benefit
TIM-HF	(Koehler	
Circulation	2011)






Participants had stable HF, so it may be that remote 
monitoring is not as effective in lower-risk patients
Tele-HF	(	Chaudhry	






Telephone-based interactive voice response system 
with a higher risk population than in the TIM-HF 
study
Patient adherence was poor, with <55% of the study 
subjects	using	the	device	3	days	per	week	by	the	end	
of the study. Interestingly, a smaller previous trial had 
shown benefit; this difference in results implies that 









Health-coaching telephone calls with monitoring 
of	weight,	BP,	HR,	and	symptoms	in	a	high-risk	
population with 50% rehospitalization rate
Nonadherence was the primary limitation, with only 
61%	of	patients	more	than	half-adherent	in	the	first	30	
days
Mayo Clinic Study 
(Takahashi	Arch	
Intern	Med	2012)







symptom assessment. Video conference capability 
was present.
Abnormal	telehealth	data	were	directed	to	PC	providers.	
It is unclear what action this drove. It might have 
caused the PC provider to direct the patient to an 
emergency department or a hospital. Could increased 







Electronic device to assess symptoms and educate 
patients	with	HF.	Abnormal	symptoms	directed	
to a monitoring nurse. Device tailored itself to 
patient’s knowledge.
Excellent adherence with use of the device. Planned and 
unplanned face-to-face HF nurse visits were higher in 
the control group. Event rates for both groups were 
lower than expected. Primary limitation appeared to be 






Pilot study, compliance eroded. However, this detected 
precursors of hospitalization for HF exacerbation with 
76% to 88% sensitivity and 85% specificity.
Abbreviations:	BP,	blood	pressure;	HF,	heart	failure;	HR,	heart	rate;	PC,	primary	care;	RPM,	remote	patient	monitoring.
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randomized HF patients to either remote patient management plus 
usual care or to usual care only and were followed up for over a year 
(Koehler et al., 2018).	The	results	showed	reduction	in	the	combined	
endpoint of percentage of days lost due to unplanned hospitalization 
and all-cause mortality. However cardiovascular mortality was simi-
lar between remote monitoring and standard care groups. Implanted 
devices that monitor pulmonary arterial pressure may be beneficial 
in	select	patients	when	used	in	structured	programs	(Dickinson et al., 




HF	patients	(Abraham et al., 2016, Carbo et al., 2018, Desai et al., 2017).	
This requires daily download of hemodynamic data and a prespecified 
medical	treatment	plan.	An	app	is	also	available	which	illustrates	pa-
tient compliance with monitoring, alerts the patient when transmis-
sions are not received, shows medication reminders, and allows for 
medication reconciliation and titration.
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4.2.1 | Mobile technologies for managing 
heart failure
The concept of coupling remote monitoring and mobile cellular 
technologies	 is	attractive	for	 the	HF	community	 (Carbo et al., 2018, 
Cipresso et al., 2012).	Heart	rate	(ECG),	BP,	and	weight	were	the	most	
frequently monitored parameters. Sensors that detect respiratory 
rate and pattern by detecting movement of the chest wall, via pres-
sure, stretch, or accelerometry, may have applications in HF. Detecting 
breathing	via	microphone	(sounds),	change	in	impedance,	or	pulse	oxi-
metry are other possible means to monitor respiratory function. Some 
of	these	modalities	could	be	integrated	into	smart	clothing	(Molinaro 
et al., 2018).
Some trials included also alert reminders of medication use, voice 
messages on educational tips, video education, and tracking of physical 
activity	(See	Section	4.6.1).	Patients	were	mostly	monitored	daily	and	fol-
lowed	for	an	average	of	6	months.	A	reduction	was	seen	in	HF-related	
hospital	days	(Carbo et al., 2018).	High	rates	of	patient	engagement,	ac-
ceptance, usage and adherence have been reported in some trials but not 
others	(Chaudhry et al., 2010, Hamilton, Mills, Birch, & Thompson, 2018).
Preliminary results using a disposable multisensor chest patch 
in	 the	LINK-HF	study	were	encouraging	 (Stehlik et al., 2020),	de-
tecting precursors of hospitalization for HF exacerbation with 
76% to 88% sensitivity and 85% specificity, 1 week before clinical 
manifestations.
4.2.2 | Hybrid telerehabilitation in patients with 
heart failure
Exercise	training	is	recommended	for	all	stable	HF	patients	(Piepoli 
et al., 2011, Ponikowski et al., 2016).	 Hybrid	 cardiac	 telerehabilita-
tion is a novel approach. Telerehabilitation is the supervision and 
performance of comprehensive cardiac rehabilitation at a distance, 
encompassing:	 telemonitoring	 (minimally	 intrusive,	 often	 involving	




(Piotrowicz, Piepoli, et al. 2016).	Various	devices	have	been	described,	
from	 heart	 rate	 monitoring	 (Smart, Haluska, Jeffriess, & Marwick, 
2005)	and	transtelephonic	electrocardiographic	monitoring	(Kouidi, 
Farmakiotis, Kouidis, & Deligiannis, 2006)	to	tele-ECG-monitoring	via	
a	remote	device	(Piotrowicz, Zieliński, et al., 2015)	and	real-time	ECG	
and	voice	transtelephonic	monitoring	(Ades et al., 2000).
Home-based telerehabilitation was demonstrated to be safe, ef-
fective with high adherence among HF patients. It improves physi-
cal	capacity	(Piotrowicz, Buchner, Piotrowski, & Piotrowicz, 2015) and 
psychological	status	(Piotrowicz, Piotrowski, & Piotrowicz, 2016),	with	
similar	 QoL	 improvement	 to	 standard	 rehabilitation	 (Piotrowicz, 
Stepnowska, et al., 2015).	The	 first	 randomized,	prospective,	multi-
center	 study	 (TELEREH-HF)	 showed	 that	 hybrid	 telerehabilitation	
and telecare in HF patients was more effective than usual care in 
improving peak VO2, 6-minute walk distance, and QoL, although not 
associated with reduction of 24-month mortality and hospitalization 
except	 in	 the	most	experienced	centers	 (Piotrowicz, Pencina, et al., 
2019, Piotrowicz, Piotrowicz, et al., 2019).
The	recent	Scientific	Statement	from	the	American	Association	
of	Cardiovascular	and	Pulmonary	Rehabilitation,	the	AHA,	and	the	
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ACC	indicates	that	home-based	rehabilitation	using	telemedicine	is	a	
promising	new	direction	(Thomas et al., 2019).
4.3 | Diabetes
Diabetes mellitus is a strong risk factor for the development of 
morbidity and mortality associated with a range of cardiovascular 
diseases.	Metabolic	 syndrome	 (elevated	 blood	 glucose	 and	 insulin	
resistance)	 acts	 via	 multiple	 mechanisms	 resultant	 in	 micro-	 and	
macrovascular complications, development of autonomic neuropa-
thy,	diastolic	dysfunction,	renal	failure,	and	AF.	Important	manage-
ment goals are lifestyle changes [e.g., diet and activity: see later 
section] to prevent disease development and tight glycemic con-
trol, especially for type 1 diabetes mellitus which demands lifelong 
rigorous	 self-monitoring	 (Balakumar, Maung-U, & Jagadeesh, 2016; 
Donnelan et al., 2019, Goudis et al., 2015, Wang, Green, Halperin, & 
Piccini, 2019, Wilkinson, Zadourian, & Taub, 2019; Wingerter, Steiger, 
Burrows, & Estes, 2020).	mHealth	modalities	 self-management	was	
recommended recently by ESC guidelines on diabetes and cardio-
vascular	diseases	to	(Cosentino et al., 2020).
Glycemic	 control	may	 reduce	AF	 development	 and	 recurrence	
(Chao et al., 2012; Chang et al., 2014; Gu et al., 2011, Otake, Suzuki, 
Honda, & Maruyama, 2009).
Mobile apps can facilitate self-management by reminding reg-
ular assessment of required parameters and medications to take 
and provide educational tools and motivational support. Regular 
transmission of blood glucose levels from patients to their physi-
cians can be based on SMS, email, or diverse web-based services. 
Bluetooth-enabled	 glucose	 meters	 are	 frequently	 used	 (Andres 
et al., 2019, Garabedian, Ross-Degnan, & Wharam, 2015).	 BlueStar	
(Welldoc,	Columbia,	MD),	first	to	receive	US	FDA	clearance	for	di-
abetes mellitus management, comes with an app which requires a 
physician prescription and enables patients to titrate insulin dosing 
by using the proprietary insulin calculator. The Freestyle LibreLink 
app	 (Abbott	 Laboratories,	 Abbott	 Park,	 IL)	 reads	 an	 associated	
continuous	glucose	monitoring	device	and	displays	trends	(Fokkert 
et al., 2017).
Stand-alone diabetes management apps have recently been re-
viewed	(Fleming et al., 2020).	Short-term	measures,	such	as	HbA1c,	
may be improved by such apps in conjunction with clinical support, 
but	 many	 have	 suboptimal	 usability	 (Veazie et al., 2018).	 Phone-
based interventions were associated with improved glycemic con-
trol	as	compared	to	standard	care	 (Fokkert et al., 2019, Liang et al., 
2011, Pillay et al., 2015, Saffari, Ghanizadeh, & Koenig, 2014).	Efficacy	
for improving glycemic control in randomized controlled trials has 
shown	mixed	results	(Agarwal et al., 2019, Quinn et al., 2011).	Meta-
analyses indicate that mobile phone interventions for self-man-
agement	 reduced	HbA1c	modestly	 by	 0.2-0.5%	over	 a	median	 of	
6-month follow-up duration, with a greater reduction in patients 
with type 2 compared to type 1 diabetes (Pal et al., 2014).	A	signif-
icant impact on clinical outcomes may affect healthcare expendi-
tures by reducing the need for in-person contact with healthcare 
providers, preventing hospital admissions, and improving prognosis. 
In a retrospective study, the use of mHealth technologies was as-
sociated with a 21.9% reduction in medical spending than a control 
group during the first year (Whaley et al., 2019). Key determinants to 
successful uptake of decision-support apps will be their user-friend-
liness and complexity and the delivery of electronic communica-
tions and feedback to the patient.
4.4 | Hypertension
Hypertension, because of its high prevalence, provides the highest 
attributable	risk	for	the	development	of	AF	(Huxley et al., 2011).
mHealth strategies for hypertension comprise a continuum 
of solutions, used by consumers or healthcare providers, and in-
cludes wireless diagnostic and clinical decision-support tools, 
aiming	to	monitor	health	status	and	improve	health	outcomes.	BP	
telemonitoring is one of the most commonly used strategies and 
includes	remote	data	transmission	of	BP	and	clinical	 information	
from patients in their home or from a community setting to a cen-
tral service, where they are reviewed by a managing physician for 
treatment	adjustments.	Several	clinical	trials	have	shown	that	BP	
telemonitoring might be more effective than usual care in achiev-
ing	 target	BP	 (Bosworth et al., 2011, Kim, Shin, Park, & Lee, 2015, 
McManus et al., 2010).	 A	 meta-analysis	 showed	 that,	 compared	
with	usual	care,	BP	telemonitoring	improved	office	systolic	BP	and	
diastolic	BP	by	3.99	mm	Hg	 (95%	confidence	 interval	 (CI):	5.06–
2.93;	P<0.001)	and	1.99	mm	Hg	(95%	CI:	−2.60	to	−1.39;	P<0.001),	
respectively (Duan et al., 2017).	 BP	 telemonitoring	 nested	 in	 a	
more complex intervention, including additional support, as face-
to-face counseling, telecounseling, education, behavioral manage-
ment, medication management, and adherence contracts, led to 
additional	and	more	sustainable	benefit	(Duan et al., 2017; Tucker 
et al., 2017)
mHealth has the potential to promote patient self-management, 
as a complement to the doctor's intervention, and encourage greater 
participation	 in	 medical	 decision-making.	 Indeed,	 the	 TASMINH4	
unblinded randomized controlled trial showed that patients who 
used	self-monitoring	of	BP	to	titrate	antihypertensives,	with	or	with-
out	telemonitoring,	achieved	better	BP	control	than	those	assigned	
to	usual	care	(McManus et al., 2018).	The	self-monitoring	group	that	
used	telemonitoring	achieved	lower	BP	quicker	than	the	self-moni-
toring group not receiving telemonitoring support, but readings were 
not significantly different at 1 year of follow-up. Cost-effectiveness 
analysis suggests that self-monitoring in this context is cost-effec-
tive	by	NICE	criteria,	that	is,	costing	well	under	£20,000	per	QALY	
(Monahan et al., 2019).
Although	mHealth	options	may	aid	hypertension	management,	
technological barriers, high costs, heterogeneity of solutions and 
technologies, and lack of standards challenge clinical implemen-
tation. The 2019 ESC guidelines on hypertension stress the im-
portance of self-monitoring and underline the potential use of 
smartphone-based solutions. Nevertheless, they do not recommend 
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the	use	of	mobile	apps	as	 independent	mean	of	BP	measurements	
(Williams et al., 2018).
4.5 | Disorders Including Sleep Apnea (See also 
Heart Failure Section 4.2.1)
Sleep disorders are widely prevalent and contribute to cardiovascular 
risk	and	arrhythmias,	especially	AF	(Daghlas et al., 2019, Hirshkowitz 
et al., 2015, Mehra et al., 2006, May et al., 2016, May, Van Wagoner, & 
Mehra,	2017),	(Institute of Medicine Report: Sleep Disorders and Sleep 
Deprivation: An Unmet Public Health Problem), (Institute of Medicine 
(US) Committee on Sleep Medicine and Research//www.ncbi.nlm.nih.
gov/books/	NBK19961).	 This	 maybe	 because	 sleep	 disturbance	 is	
intimately tied to circadian rhythms and sympatho-vagal balances 
(Burgess, Trindert, Kim, & Luke, 1997).	Standard	sleep	disorder	diag-
nostics have been validated but require technical support for data 
acquisition and scoring. For example, polysomnography has long 
been considered the gold-standard for acquisition of rich multimodal 
cardio-neurorespiratory objective physiologic data to ascertain 
sleep architecture, total sleep time, and cardiorespiratory abnor-
malities and is primarily used for the diagnosis of obstructive sleep 
apnea.	 Actigraphy	 has	 the	 advantage	 of	 collecting	 objective	 data	
over days and nights to characterize sleep–wake patterning and pro-
vide measures of total sleep time, sleep efficiency, and sleep onset 
latency in addition to surrogate circadian measures. However, such 
tests are obtrusive and expensive.
•	 Treating	sleep	apnea	may	reduce	AF	burden	(Qureshi et al., 2015, 
Youssef et al., 2018).
Consumer technology directed to sleep medicine may revolu-
tionize the detection and treatment of sleep disorders. Since such 
apps are preinstalled on many smartphones, sleep tracking may 
be	among	the	most	widely	applied	facets	of	mHealth	(Khosla et al., 
2018).	 Applications	 include	 mobile	 device	 applications,	 wearable	
devices,	embedded	devices	(in	the	individual’s	sleep	environment),	
rings (https://bodim etrics.com/produ ct/circu l-sleep -and-fitne ss-
ring),	integration	of	accessory	diagnostic	monitoring	(e.g.,	oximetry,	
ECG	monitoring),	and	sleep	therapy	adherence	monitoring.	Several	
commercially available wearable devices measure total sleep time 
accurately, but not more detailed parameters such as sleep effi-
ciency	and	different	sleep	stages	(Mantua, Gravel, & Spencer, 2016).	
Preliminary data suggest that wearable devices may be capable of 
detecting sleep apnea with good accuracy compared to gold-stan-
dard	polysomnography	(Selvaraj et al., 2014)	and	transform	the	ap-
proach to sleep disorder screening, diagnosis, and treatment. Sleep 
irregularity diagnosed by 7 day wrist actigraphy was linked to risk of 
cardiovascular	events	(Huang, Mariani, & Redline, 2020). Preliminary 
studies indicated that use of wearables may permit behavior mod-
ifications	 that	 improve	 sleep	 quality	 (Berryhill et al., 2020).	 In	 this	
regard, mHealth applications to sleep diagnosis and treatment 
promise facilitation of rhythm control.
4.6 | Lifestyle (See Figure 5)
4.6.1 | Physical activity
Physical activity is any bodily movement from skeletal muscle con-
traction	to	 increase	energy	expenditure	above	basal	 level.	Athletic	
activity varies from recreational sports to competitive events. There 
is a compelling evidence that regular aerobic exercise at the levels 
recommended	by	Physical	Activity	Guidelines	Advisory	Committee	
reduces the risk of a variety of cardiovascular conditions, includ-
ing	AF	 (Everett et al., 2011, Mozaffarian, Furberg, Psaty, & Siscovick, 
2008, Piercy et al., 2018).	However,	the	majority	of	the	population	is	
not	engaged	in	physical	activity	at	the	recommended	levels	(Piercy 
2018).	Among	patients	with	cardiovascular	disease,	patient	activity	
measured automatically by ICDs correlated with survival following 
ICD	 implantation	 (Kramer et al., 2015). Fitness represents an enor-
mous market for mobile technologies and significant opportunity 
to improve the health of a wide range of mHealth consumers. In 
2017,	over	318,000	“fitness	and	health”	apps	were	available,	almost	
double	the	number	two	years	prior	(IQUIVA Institute 2017).	Many	of	
these recreational apps monitor daily physical activity and support a 
healthy lifestyle by counting the number of steps daily, online train-
ing,	and	motivation	coaching	(McConnell et al., 2018).
•	 Cardiorespiratory	fitness	has	an	inverse	relationship	to	AF	burden	
(Faselis  et al., 2016).
• Improvement in exercise capacity of 2 METs in overweight indi-
viduals	may	double	freedom	from	AF	(Pathak et al., 2015).
Consumer-grade fitness technology includes individual fitness 
trackers that can stand alone, a fitness tracker that is coupled with 
a companion app, or an app that can be downloaded onto a smart-
phone, which then utilizes various features of the smartphone to 
measure activity and sleep. The accuracy of these measurements 
varies between different products and between measures within the 
same	product	(Rosenberger, Buman, Haskell, McConnell, & Carstensen, 
2016).	 Furthermore,	while	 step-counting	 is	 long	 established,	mea-
suring	 the	 intensity	of	 exercise	 is	more	 complex.	Although	 fitness	
technology has the exciting potential to increase physical activity 
by promoting goal setting and providing feedback, its effectiveness 
in	motivating	positive	behavioral	change	remains	unclear	(Sullivan & 
Lachman, 2017).
One cautionary tale is the study by Jakicic et al. that examined 
the effectiveness of a lifestyle intervention with or without a fitness 
tracker	(Jakicic et al., 2016).	Two	groups	received	instruction	to	pro-
mote physical activity and dietary restriction. Six months into the in-
tervention, half of the participants were provided with an upper arm 
fitness tracker and web-based support accompanying the device. 
The other half logged and tracked their activity and diet on a study 
website. Of note, the group that wore the tracker lost less weight 
than the group who did not. Moreover, changes in physical activity 
between the two groups were not significantly different. These re-
sults cast doubt on the effectiveness of fitness trackers in promoting 
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greater physical activity, and thus, further data are required to as-
sess	the	impact	of	this	approach	(See	Section	5).
Competitive athletes
These are a unique category. Endurance athletes may have increased 
AF	risk	(Abdulla & Nielson, 2009, Anderson et al., 2013).	Remote	eval-
uation of ECG recordings may be useful in countries that perform 
preparticipation	ECG	screening	(Brunetti et al., 2014, Orchard et al., 
2019).	 Mobile	 devices	 and	 apps	 provide	 complex	 data	 which	 can	
be	used	as	a	self-monitoring	tool	for	managing	training	(Aroganam, 
Manivannan, & Harrison, 2019, Li et al., 2016, Peake, Kerr, & Sullivan, 
2018, Peart, Balsalobre-Fernandez, & Shaw, 2019, Seshadri et al., 2019).	
Exercise load and performance level can be accessed on a regular 
basis by coaches as well as athletes. Training guided by daily moni-
toring of HRV parameters has also been proposed, but data are 
limited	 (Coppetti et al., 2017, Dobbs et al., 2019, Singh et al., 2018).	
Mobile devices provide the possibility of online real-time monitoring 
during indoor and outdoor training and competitions. Monitoring of 
heart rate provides both information on performance and level of 
training but can also provide valuable information regarding heart 
rhythm	irregularity	suggestive	of	arrhythmias.	Any	kind	of	paroxys-
mal arrhythmia related to sport participation and detected by mobile 
devices designed merely for heart rate assessment should trigger 
further cardiological evaluation. Having in mind data indicating that 
sports participation may be associated with higher risk of develop-
ment	of	AF	mobile	devices	may	serve	as	valuable	screening	tool	for	
AF	detection.
Importantly, mHealth solutions enable easy access to athletes’ 
medical data. The latter approach can be of special interest in man-







compliant with all recommendations and 42% are compliant with only 
0-2	recommendations	(Folsom et al., 2011).	Although	there	is	ample	ev-
idence that weight loss and maintaining an ideal weight are beneficial 
in	 reducing	AF	burden	and	 symptoms,	 compliance	with	 this	 recom-
mendation is poor; the reasons include among others, inability to track 
food	intake	(Abed et al., 2013, Donnellan et al., 2019, Pathak et al., 2015).
• Weight loss combined with risk factor modification is a Class 1 
(B-R)	recommendation	in	treatment	of	AF	(January et al., 2019)
• >10%	weight	reduction/	target	BMI	<27 kg/m2	reduces	AF	bur-
den	(Pathak et al., 2015).
There are currently many consumer-oriented mobile phone-
based	 applications	 (apps)	 designed	 for	 tracking	 food	 intake,	 but	
their utility for use in carbohydrate counting is limited due their de-
sign	(El-Gayar, Timsina, & Nawar, 2013).	Commonly,	these	consum-
er-oriented	apps	 require	multiple	 steps.	As	 an	example,	 the	user	
types in the food consumed and then scrolls through the search 
results to match with the program’s food and nutrient database. 
Next, after finding a matching food type, the user must estimate 
and enter an amount. These apps require significant user input 
and time burden along with high possibility of error. In addition, 
they are also plagued by uncertain accuracy. Recently, research 
has shown that nutrient calculations from leading nutrition track-
ing apps tended to be lower than results from using 24-hour recall 
with	analysis	by	the	Nutrition	Data	System	for	Research	 (NDSR),	
a	 research-level	 dietary	 analysis	 software	 (Griffiths, Harnack, & 
Pereira, 2018).
By	contrast,	a	visual	image-based	app,	such	as	the	Technology-
Assisted	Dietary	 Assessment	 (TADA)	 system,	 directly	 addresses	
the	 aforementioned	 shortcomings	 (Boushey, Spoden, Zhu, Delp, 




that communicates with the mFR, processes, and stores the food 
images.	Using	the	TADA	system,	a	person	takes	a	photograph	of	
the meal they are planning to eat using their smartphone’s camera. 
The	use	of	geometric	models	has	permitted	the	TADA	system	to	
use a single image of a meal to estimate portion size to within 15% 
of	the	actual	amount	(Fang, Liu, Zhu, Delp, & Boushey, 2015).	Hence,	
smartphone-based	 technology	such	as	 the	TADA	system	can	 fa-
cilitate tracking of food intake, which in turn can potentially help 
with weight management.
Despite the profusion of diet- and weight-related apps, and the 
interest in weight loss in the community, there remains a dearth of 
high-quality	evidence	that	these	apps	are	actually	effective	(Dounavi 
& Tsoumani, 2019).	There	remains	a	need	for	further	evidence	devel-
opment before specific apps or other mHealth technology can be 
recommended or prescribed.
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5  | PATIENT SELF-MANAGEMENT—
INTEGR ATED CHRONIC C ARE
Generally, structured management programs inclusive of intensive 
patient	 education	 may	 improve	 outcomes	 (Hendriks et al., 2012; 
Lin et al., 2014; Angaran et al., 2015).	 These	may	 be	 facilitated	 by	
mHealth.
5.1 | Patient engagement
mHealth offers the opportunity to reach more patients more ef-
fectively. It may promote patient engagement through ease of 
access and wider dissemination to regions and communities who 
may not access health care through traditional modes due to 
cost, time, distance, embarrassment/stigma, marginalized groups, 
health inequities, etc. In this way, mHealth may facilitate infor-
mation sharing and interaction between patients and HCPs with-
out	 the	 need	 for	 an	 elaborate	 infrastructure	 (Chow, Ariyarathna, 
Islam, Thiagalingam, & Redfern, 2016, Walsh, Topol, & Steinhubl, 
2014)	(Figure	6).	Apps	may	aid	HCPs	to	explain	the	condition	and	
treatment options, utilizing videos, avatars, and individualized risk 
scores, enabling greater patient understanding and encouraging a 
two-way exchange of information to achieve a concordant deci-
sion about treatment.
Patients’ access to their own health data
A	recent	HRS	statement	advocates	for	transparent	and	secure	ac-
cess	by	patients	 to	 their	 digital	 data	 (Slotwiner et al., 2019).	 This	
enables active participation and appropriate self-management. 
For	 instance,	 many	 patients	 with	 AF	 are	 interested	 in	 seeing	
their	 AF	 burden	 and	 physiologic	 data,	 similarly	 to	 patients	 with	
hypertension	 tracking	 their	 BP	 or	 patients	 with	 diabetes	 track-
ing their glucose. Recent systematic reviews of technology-based 
patient-directed interventions for cardiovascular disease suggest 
that engaging elements include self-monitoring of symptoms and 
measurements, daily tracking of health behaviors, disease edu-
cation,	 reminders,	 and	 interaction	 with	 HCPs	 (Coorey, Neubeck, 
Mulley, & Redfern, 2018, Gandhi et al., 2017, Park, Beatty, Stafford, 
& Whooley, 2016, Pfaeffli Dale, Dobson, Whittaker, & Maddison, 
2016).	In	some	cardiovascular	conditions,	self-management	(with-
out	any	HCP	input)	improved	key	outcomes	(Hagglund et al., 2015, 
Varnfield et al., 2014).
The model requires that patients assume responsibility and ac-
countability for tracking conditions effectively and taking corrective 
measures. Possibly, this may be facilitated by data organization to 
present salient elements in a format comprehensible to the lay pub-
lic.	Active	role	of	patients	in	decision-making	regarding	the	choice	of	
treatment	has	been	underlined	by	AF	clinical	guidance	documents.	
Patients	 with	 AF	 are	 encouraged	 to	 be	 involved	 in	 decision-tak-
ing through better understanding of their disease, which helps to 
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improve communication between patients, their families, and doc-
tors and improves patients’ adherence to prescribed therapy. Two 
applications	 in	 AF—one	 for	 patients	 and	 the	 other	 for	 healthcare	
providers—have	 been	 developed	 by	 CATCH	 ME	 Consortium	 in	
collaboration	with	 European	 Society	 of	 Cardiology	 (Kotecha et al., 
2018),	but	these	have	yet	to	be	formally	tested.	In	China,	Guo	and	
colleagues	 (Guo, Chen, Lane, Liu, Wang, & Lip, 2017)	 demonstrated	
that	the	mobile	atrial	fibrillation	(mAFA)	app,	incorporating	decision	
support, education, and patient engagement, significantly improved 
AF	patients’	knowledge,	medication	adherence,	quality	of	 life,	and	
satisfaction to anticoagulation compared to usual care.
Limitations should be recognized:
• Demands of self-management may be excessive for even well in-
tentioned patients required to be facile with setting up their own 
medical monitoring device, assessing frequency of download, in-
terpreting and acting on data when required, and troubleshoot-
ing. These are not trivial challenges.
5.2 | Behavioral modification
Individual health status has been found to be a strong independ-
ent	predictor	of	mortality	and	cardiovascular	events	(Rumsfeld et al., 
2013).
mHealth may catalyze positive behavioral change and facilitate 
health	care.	An	 induced	healthy-user	effect	was	 likely	the	basis	of	
survival benefit among CIED patients adhering more closely to re-
mote	management	 (Varma et al., 2015).	mHealth	may	 support	 pa-
tients	with	text	messaging	(Chow et al., 2015)	or	mobile	applications	




port to an individual at the correct time, with the ability to adjust 
depending on the person’s current internal and situational factors 
(Nahum-Shani et al., 2018).	mHealth	technology	is	an	ideal	platform	
to	facilitate	JITAIs	by	providing	“real-time”	personalized	information,	
which	 can	 be	 utilized	 to	 inform	 the	 intervention	 delivered.	 JITAIs	
have been widely employed for health promotion and to support 
behavior	change,	but	evidence	of	their	efficacy	is	limited	(Gustafson 
et al., 2014, Patrick et al., 2009, Riley, Obermayer, & Jean-Mary, 2008).	
Timing is integral to the perception of benefit, as is receptivity to 
accept	 and	 use	 the	 support	 (Nahum-Shani et al., 2015).	 Bespoke,	
multi-faceted mHealth tools, with motivational messages and incor-
porating	gamification,	are	most	engaging	(Coorey, Neubeck, Mulley, & 
Redfern, 2018, Gandhi et al., 2017, Park, Beatty, Stafford, & Whooley, 
2016, Pfaeffli Dale, Dobson, Whittaker, & Maddison, 2016).
Incorporation	of	gamification	strategies	(e.g.,	rewards,	prizes,	av-
atars, performance feedback, leader-boards, competitions, and social 
connection)	into	mHealth	promotes	patient	engagement	and	sustains	
healthy	 behaviors	 (Blondon, Meyer, Lovis, & Ehrler, 2017, Cugelman, 
2013, Edwards et al., 2016, Johnson et al., 2016, Sardi, Idri, & Fernandez-
Aleman, 2017).	 However,	 a	 recent	 systematic	 review	 demonstrated	
that	only	4%	 (64/1680)	of	English-language	“top-rated”	health	apps	
incorporated	≥1	gaming	feature	(Edwards et al., 2016).	There	are	lim-
ited hypothesis-generated data for these mHealth interventions, and 
their efficacy in this context is as yet unmeasured. Self-regulatory be-
havior	change	techniques,	such	as	feedback	and	monitoring	(includ-
ing	self-monitoring),	comparison	of	behavior,	rewards,	incentives	and	
threats, and social support, are the most common behavior change 
techniques employed in gamification apps and are frequently utilized 
in successful nongaming apps targeting health promotion and sec-
ondary	prevention	 (Conroy, Yang, & Maher, 2014, Direito et al., 2014, 
Edwards et al., 2016).	Engaging	with	apps	 involving	gamification	can	
also improve emotional well-being through feelings of accomplish-
ment	and	social	connectivity	(Johnson et al., 2016).
5.3 | Patients as part of a community
Incorporation of a patient as part of a wider community may offer 
benefits.	 Social	 networking	 is	 widely	 used	 for	 health	 (Fox 2011).	
Online	communities	enable	individuals	to	“meet,”	share	their	experi-
ences, discuss treatment, and receive and provide support from peers, 
patient	organizations,	or	HCPs	 (Fox, 2011, Swan, 2009, Swan, 2012).	
While crowdsourcing via the Internet and social networks allows col-
lective sharing and exchange of information from a large number of 
people, the integrity and accuracy of such information remains largely 
un-vetted	and	as	such	may	be	unreliable	(Besaleva & Weaver, 2014).
5.4 | Maintaining patient engagement
Sustaining healthy behaviors and minimizing intervention fatigue is 
paramount	to	long-term	maintenance.	Although	mHealth	may	help	
to maintain motivation, available data demonstrate significant attri-
tion with mHealth interventions targeting risk factors and chronic 
conditions, even when people report liking the intervention and 
have	 purchased	 it	 (Chaudhry  et al., 2010, Flores Mateo, Granado-
Font, Ferré-Grau, Férre-Grau, & Montaña-Carreras, 2015, Fukuoka, 
Gay, Haskell, Arai, & Vittinghoff, 2015, Morgan et al., 2017, Owen et al., 
2015, Simblett et al., 2018, Whitehead & Seaton, 2016, Endeavour 
Partners, 2017, Perez et al., 2019).
A	representative	patient’s	experience	is	described	below:
A	few	years	ago	(2017),	a	friend	told	me	about	a	new	
app that he had installed on his iPhone that would 
allow him to measure his heart rate through a finger-
tip pulse. Having an irregular heartbeat, under control 
through medication, I was very interested to try the 
new app. I thought it would provide me the opportu-
nity to know more about myself, specifically how my 
heart operated under stress and at different times of 
day, before, during, and after physical exertion of a 
variety of my favorite sports and pastimes like tennis, 
golf, biking, and fly fishing.
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At	first,	I	was	quite	satisfied	with	the	rudimentary	cal-
culations. Then, I noticed during my international busi-
ness travels that the device was often down during 
US nighttime hours during which time I thought the 
‘hosts’ were making repairs or improvements. I also 
noticed that there were several radically incorrect 
readings especially during early morning hours. It 
simply wasn’t performing up to the standards of more 
traditional monitoring devices. I found as well that 
the host’s increasing attempt to up-sell to premium 
packages and other online health management tools 
became quite burdensome.
Before	long,	I	felt	almost	addicted	to	the	device	and	
ultimately quit on it altogether. In retrospect, I believe 
that if I had had a proper introduction to the device by 
a trained medical specialist, I might have had a differ-
ent expectation of this online tool, how to use it and 
how to interpret its data output.
Understanding the basis for health-protective behavior is vital 
(Dunton, 2018).	Many	apps,	including	those	from	national	heart	foun-
dations	 (American Heart Association, 2019, British Heart Foundation, 
2014, Canadian Heart and Stroke Foundation, 2014, National Heart 
Foundation of Australia, 2014),	are	available	to	support	healthy	life-
style choices, but their efficacy remains largely untested or is limited 
by	design	features	(i.e.,	small	sample	sizes,	selection	bias,	etc.).	Cost,	
service connectivity, and credibility of information sources are im-
portant factors. However, patient engagement may be jeopardized 
by	worries	 about	 privacy	 and	 personal	 data	 security	 (Burke et al., 
2015, Chow, Ariyarathna, Islam, Thiagalingam, & Redfern, 2016, Kumar 
et al., 2013, Steinhubl, Muse, & Topol, 2015).
Continued clinic support
The level and duration of clinic support needed will likely depend on 
condition monitored and goals for treatment. Reduction in compul-
sory routine in-clinic evaluations and reliance on continuous remote 
monitoring improved retention to long-term follow-up of patients 
with	CIEDs	(Varma, Michalski, Stambler, Pavri, & TRUST Investigators, 
2014).	In	one	HF	trial,	gain	was	related	to	the	period	of	remote	in-
struction. Whether this indicates that efficacy of the active program 





can potentially exacerbate disparities in health care along sociode-
mographic lines.
Older	people	are	perceived	to	engage	less	with	mHealth.	A	2017	
Pew Research Center survey found that 92% of 18-29 year olds 
and	74%	of	age	50-64	year	olds	own	a	 smartphone	 (Smith, 2017).	
However, the lack of familiarity with the technology and access to 
mobile devices, rather than lack of engagement per se, remain the 
principal	barriers	(Coorey, Neubeck, Mulley, & Redfern, 2018, Gallagher 
et al., 2017, Tarakji et al., 2018).	Older	users	of	mHealth	prefer	per-
sonalized information, which is clearly presented and is easy to nav-
igate	(Neubeck et al., 2015).
There is also disparity across the educational spectrum, with 
smartphone usage in 57% of the population with less than high 
school education and 91% of the population who graduated from 
college.
Smartphone use differs by income, with smartphone usage in 
67%	of	the	population	with	income	annual	≤	$30,000	and	93%	of	the	
population	with	income	≥	$75,000	(Mobile Fact Sheet, 2018).	Limited	
evidence	from	the	USA	suggests	that,	although	there	is	some	vari-
ation in the mHealth use related to ethnicity, black and Hispanic 
Americans	 are	not	 disadvantaged	 (Martin, 2012).	mHealth	permits	
information and apps to be tailored appropriately for language, liter-
acy	levels	(including	“text	to	speech”	technology),	and	cultural	differ-
ences	to	promote	engagement	 (Coorey, Neubeck, Mulley, & Redfern, 
2018, Neubeck, Cartledge, Dawkes, & Gallagher, 2017, Redfern et al., 
2016).
There is heterogeneity of mHealth availability among different 
countries	 (Varma, 2020).	 Even	 some	 of	 the	 best	 studied	 and	 FDA	
and CE approved technologies described here may be currently 
unavailable due to regulatory or marketing rules or simply unaf-
fordable to either individuals or healthcare systems in many other 
countries.
As	 healthcare	 systems	 leverage	 and	 incorporate	 smart-
phone-based technology in their workflow and processes, a strategy 
is needed in parallel to ensure that those who do not have access to 
smartphone-based technology will continue to receive appropriate 
high-quality care. This critical initiative will require consensus and 
action among all stakeholders including HCPs, hospital systems, 
insurance providers, and state and federal government agencies. 
Thus enabled, mHealth promises improved patient outcomes in re-
source-limited	areas	(Bhavnani et al., 2018).
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mHealth may have particular impact on trials of heart rhythm dis-
orders. Traditionally, clinical trials testing drugs and devices for ar-
rhythmias utilized time-to-event outcomes and analyses, such as first 
recurrence	of	AF	after	a	blanking	period	(Piccini et al., 2017).	Patients	
randomized to the control and intervention would be monitored in-
termittently, either with ambulatory devices and/or in-clinic visit. 
Such monitoring had limited sensitivity for recurrent arrhythmias, 
including symptomatic and asymptomatic episodes. Furthermore, 
time-to-first event may not accurately capture reductions in arrhyth-
mia burden, which have also been shown to be beneficial in recent 
randomized	trials	(Andrade et al., 2019).	While	CIEDs	such	as	pace-
makers and defibrillators can be leveraged for continuous monitor-
ing	(Varma, Stambler, & Chun, 2005),	these	studies	do	not	generalize	
to broader CIED-free populations. ILRs may have a potential role, 
but are costly and unless used for clinical indications, difficult to jus-
tify simply for study event ascertainment.
There are a variety of free-standing handheld ECG monitors, some 
of	which	have	automated	AF	detection	(Table	1).	However,	many	do	
not have cellular or networking capability and therefore generally 
cannot transmit data or findings in real time. This is where smart- or 
mobile-connected arrhythmia and pulse detection technologies have 
significant promise. These may enhance detection and measurement 
of clinical outcomes while also allowing for remote or virtual data 
collection without the need for site-based study visits. Examples in-
clude remote rhythm assessment with single- or multilead ECGs from 
smartphone or smartwatch-based technologies and automatic as-
certainment of hospitalizations using smartphone-based geofencing 
(Nguyen et al., 2017).	These	operational	enhancements,	in	turn,	can	im-
prove participant satisfaction, reduce cost, improve study efficiency, 
and	facilitate	or	expand	enrollment.	An	example	is	the	ongoing	Health	
eHeart study, a site-free cardiovascular research study that leverages 
self-reported data, data from wearable sensors, electronic health re-
cords,	and	other	importable	“big	data”	to	enable	rapid-cycle,	low-cost	
interventional	 and	 observational	 cardiovascular	 research	 (https://
www.healt	h-ehear	tstudy.org/).
Screening
Two recent large-scale studies highlight the potential advantages of 
mHealth	for	AF	screening	and	treatment.
• The Apple Heart Study
This was a highly pragmatic, single-arm investigational device 
exemption study designed to test the performance and safety of a 
PPG-based	irregular	rhythm	detection	algorithm	on	the	Apple	Watch	
for	identification	of	AF	(Perez et al., 2019,	Turakhia	et	al.,	2019).	The	
study	was	 a	 siteless	 “bring	 your	own	device”	 study,	 such	 that	par-
ticipants needed their own compatible smartphone and watch to 
enroll	online.	All	 study	procedures,	 including	eligibility	verification,	
onboarding, enrollment, and data collection, were performed via the 
study app, which could be downloaded from the app store. If a partic-
ipant received an irregular pulse notification, then subsequent study 
visits were done via video conferencing to study physicians directly 
with the app. The study enrolled over 419,000 participants without 
pre-existing	AF	 in	 just	 an	 eight-month	period,	 in	 large	part	 due	 to	
the	pragmatic,	virtual	design,	and	easy	accessibility	 (Figure	4).	The	
algorithm was found to have a positive predictive value of simulta-
neous	ECG-confirmed	AF	of	0.84	 (Perez et al., 2019).	Only	0.5%	of	
the enrolled population received any irregular pulse notification, but 
3.2%	of	those	age	≥	65	years	received	notifications.	However,	only	
153/450	(34%)	patients	had	AF	detected	by	a	subsequent	single	ECG	
patches after the irregular rhythm notification was received. This 
may	reflect	the	paroxysmal	nature	of	early-stage	AF	rather	than	ex-
plicit	false	positives.	Because	the	study	only	administered	ECG	patch	
morning to those with irregular rhythm notification rather than then 
entire cohort or to negative controls, the negative predictive value 
was	not	estimated.	It	should	be	noticed	that	the	Apple	Heart	Study	
was	in	a	population	without	diagnosed	AF;	test	performance	and	di-
agnostic yield could be considerably different in a population with 
known	AF,	and	this	software	is	not	approved	for	use	for	AF	surveil-
lance	in	established	AF.
• The Huawei heart study
A	 similar	 study	 was	 performed	 using	 smart	 device-based	
(Huawei	 fitness	band	or	smartwatch)	PPG	technology	 (Guo et al., 
2019).	 The	 algorithm	 had	 been	 validated	with	 over	 29	 485	 PPG	
signals before commencement of the trial. More than 246,000 
people downloaded the PPG screening app, of which about 187 
000	individuals	monitored	their	pulse	rhythm	for	7	months.	AF	was	
found	in	0.23%	(slightly	lower	than	Apple	Heart,	possibly	due	to	a	
younger	 and	 healthier	 enrolled	 cohort).	 Validation	was	 achieved	
in	87%	(PPV	>90%)	compared	to	34%	in	Apple	Heart.	The	results	
indicated that this was a feasible frequent continuous monitoring 
approach	 for	 the	 screening	 and	 early	 detection	 of	 AF	 in	 a	 large	
population.
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A	significant	observation	was	that	clinical	decision-support	tools	
provided enabled management decisions, for example, almost 80% 
high-risk patients were anticoagulated. Subsequent enrollment into 
the	mAFA	II	trial	showed	significantly	reduced	risk	of	rehospitaliza-
tion	and	clinical	adverse	events	(Guo et al., 2020).	These	trial	results	
encourage	incorporation	of	such	technology	effectively	into	the	AF	
management pathways at multiple levels, that is, screening and de-





(MobiHealthNews, 2020, Varma, 2020).
Point of Care





lar approach has been proposed for rhythm-guided use of direct 
OACs	 in	 lower-risk	 AF	 patients	 with	 infrequent	 episodes	 either	
spontaneously or as the result of a rhythm control intervention in-
cluding drugs and ablation; a randomized trial is in development 
(Passman et al., 2016).	The	use	of	smartwatch-guided	rate	control	
as a treatment strategy could also be tested, as this may provide a 
more personalized approach rather than prior randomized trials of 
lenient versus strict rate control that used population level rather 




This is key to application of results from trials. mHealth is widely 
available and often simple to apply and wear.
a. Older individuals and those with low health literacy may 
find	 technologies	 difficult	 to	 use	 (5.5	 Digital	 Divide),	 and	 this	
may be compounded by disease state, for example, previous 
stroke.
b. Cost and service plans associated with smartphones and smart-
watches may preclude their use in lower socioeconomic popula-
tions who are already under-represented in clinical trials and in 
many geographies.
Thus,	patients	who	volunteer	in	mHealth	studies	in	the	USA	are	
more likely to be a white/non-Hispanic, more educated, and less 
likely to have disease.
• Adherence
mHealth-based evaluation of clinical endpoints may be con-
founded if adherence is low, particularly if there are no sec-
ondary	means	of	endpoint	assessments	 (Guo, Vittinghoff, Olgin, 
Marcus, & Pletcher, 2017).	Virtual	designs	may	be	more	suscepti-
ble to the loss of participant engagement. For example, if mon-
itoring is completely reliant upon mobile health technology and 
there are no traditional measures or in-person visits to assess 
arrhythmia, then significant missing data due to low-adherence 
may become a major limitation that could imperil the validity and 
generalizability of the findings. For example, among the 2,161 of 
the 419,297 that received an irregular pulse notification in the 
Apple	Heart	Study,	only	945	completed	a	subsequent	protocoled	
first study visit. Of these 658 ambulatory ECG patches shipped, 
there	were	 only	 450	with	 returned	 and	 analyzable	 data	 (Perez 
et al., 2019).
Development of effective strategies to increase retention and 
maintain high engagement remains an unmet need and is an area 
ripe for more research.
• Outcomes
These are key to adoption and reimbursement. More specifically, 
the clinical and prognostic impact of new outcome measures based 
on mobile health technologies may not be clear.
This	is	important	for	AF.	For	example,	how	do	changes	in	AF	bur-




matters for a variety of important clinical endpoints, including 
stroke,	HF,	and	death	(See	Section	3.1.3)	 (Chen et al., 2018, Glotzer 
et al., 2009, Kaplan et al., 2019, Piccini et al., 2019, Wong et al., 2018).	
Does	pill-in-the-pocket	DOAC	 treatment	of	PAF	adequately	 cover	
the	risk	of	stroke?	Some	measures	remain	less	well	studied,	like	the	
occurrence of irregularity with a wearable pulse-based monitor sys-
tem, particularly without ECG confirmation.
Since these mHealth prediagnostic or diagnostic tools may 
then be directly tied to initiation or termination of treatment, rig-
orous evaluation of clinical safety and efficacy will be required 
and, in some cases, warrant a combined drug-device regulatory 
approval.
Despite these challenges, there is enormous potential for pa-
tients to use these technologies to self-monitor their arrhythmia 
treatment	and	extend	this	to	manage	comorbidities	(See	Section	
4).	The	process	of	data	transparency	and	accessibility	to	the	pa-
tient may improve the patient’s engagement with their overall 
care, even if the data are not directly actionable by the patient. 
The	restrictions	to	clinic	access	during	the	SARS-Cov-2	pandemic	
have	accelerated	the	adoption	of	mHealth	solutions	(Varma et al., 
2020).	 ECGs	 for	 clinical	 trials	 were	 recorded	 by	 smart	 devices	
and assessed at virtual visits instead of routine in-person eval-
uations. In some cases, the entire management of clinical trials 
went online.
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7  | OPER ATIONAL CHALLENGES
7.1 | Healthcare System—Ehealth Monitoring and 
Hospital Ecosystem
Transmission
A	 fundamental	 but	 as	 yet	 unresolved	 challenge	 of	 incorporating	
mHealth into clinical practice is the channel of data communica-




CIEDs: Experience with CIEDs provides a framework. CIEDs gen-
erate voluminous quantities of eHealth data. In a single patient, this 
may be generated from distinct sources, that is, remote monitoring 
and in-person interrogations. Transmission from remote monitoring 
has been well worked out: data flow from the CIED to the remote 
transceiver and then to the manufacturer’s server for access by in-
dividual practices. Unfortunately, this is usually retrieved in an image 
format rendering the granular data uninterpretable by the practice’s 
electronic	 health	 record	 (EHR).	When	 shared	with	 the	 patient,	 the	
image file is posted on the EHR’s patient portal. These files are dif-
ficult for physicians to interpret and practically uninterpretable by 
the lay public. In order to engage patients and caregivers, the data 
will need to be provided in a format that enables the lay public to 
get	a	high-level	summary	of	key	features	(such	as	battery	status	and	
remote	monitor	function	status)	with	explanations	and	the	ability	to	
drill down to the more granular details for those individuals who wish 
to do so.
Consumer digital health product data: Consumers are rapidly 
adopting products to monitor their health status for early detection 
of abnormalities as well as for managing chronic diseases. These 
tools empower and engage patients in managing their health, but 
the very basic task of sharing the data with their healthcare provider 
presents challenges. From a technical standpoint, many EHR portals 
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do not permit patients to send attachments. Therefore, the patient 
and provider are left using email, which is not considered secure or 
HIPPA	or	GDPR	compliant.	Even	if	the	EHR	portal	accepts	attach-
ments, incorporating the digital health data into the EHR remains ad 
hoc and inconsistent. The logistical and practical concerns frighten 
many care providers into discouraging their patients from using 
these devices. Concerns among providers include the fear of being 
inundated with unnecessary transmissions to review as well as the 
concern	that	patients	may	send	inappropriate	data,	for	example,	BP	
or glucose monitoring data to their electrophysiologist. Cloud-based 
storage may avoid some of these challenges.
Interoperability—Lack of organized infrastructure to 
receive incoming the data
Assimilating	the	data	obtained	from	digital	health	tools,	whether	im-
plantable or wearable, is proving to be one of the greatest clinical 
challenges. Clinicians feel increasingly burdened as both the volume 
of data as well as the sources of data increase. Creating the nomen-
clature and data models that would enable the information to be 
incorporated in the electronic medical record is less a technical chal-
lenge, but more a political challenge. It requires a consensus from 
the clinical community regarding definitions of the terminology and 
agreement on what data are required. For example, for pacemakers, 
there must be agreement on the definition of battery longevity, pac-
ing thresholds, mode switch, etc. For CIEDs, this work has been done 
(https://www.iso.org/stand	ard/63904.html, Slotwiner et al., 2019).	
The next step is for EHR vendors to support the agreed-upon no-
menclature and the data standard in which it is communicated. With 
these 2 building blocks, digital health data can be assimilated into the 
clinical workflow, enabling healthcare providers to review, manage, 
and document clinical impressions and recommendations within the 
environment of their EHR. This work is ongoing in the domain of 
CIEDs but has not started for wearable devices. It requires a coali-
tion of clinicians, engineers, regulatory agencies as well as regulatory 
and/or	financial	 incentives	for	vendors.	A	high-efficient	computer-
ized system with huge storage is necessary infrastructure and may 
provide the platform for predictive analytics.
Interoperability—Lack of organized infrastructure to 
transmit data and instructions
There is interest in mHealth to support patients with text messag-
ing	(Chow et al., 2015)	or	mobile	applications	to	remind	patients	of	
medication doses and times or medical appointments. To be effec-
tive, this requires synchronization with healthcare providers, ideally 
by integration with the EMR, allowing changes in medications and 
doses, as well as appointments, to flow between patients and clini-
cians	in	an	accurate	and	bidirectional	manner	(Spaulding et al., 2019).	
However, EMR systems software is lacking such functionality and 
interoperability	at	this	point	(Ratwani et al., 2018).
7.2 | Cybersecurity guidance for mHealth devices
Interconnection of medical devices and clinical data promises facili-
tation of clinical care but also creates opportunities for intrusions by 
maleficent	actors	(i.e.,	hackers)	to	disable	systems	and/or	access	pri-
vate	health	 information	 (PHI)	 (Jalali, Russell, Razak, & Gordon, 2019, 
Kruse, Frederick, Jacobson, & Monticone, 2017).	 The	 motivation	 is	
largely financial. Healthcare facilities and medical device companies 
present attractive targets because a number of attack strategies can 
yield large financial rewards:
1.	 Ransomware.	A	hospital’s	 systems	can	be	 locked	out	 (e.g.,	 data	
may	 be	 encrypted)	 until	 the	 attacker	 is	 paid	 (Mansfield-Devine, 
2016, Network Security 2016)
2.	 Theft	and	sale	of	patient	data	(i.e.,	PHI).
3.	 Company	attack.	A	hacker	may	identify	flaws	in	a	system	or	de-
vice, short the company’s stock, and then make the flaws public. 
Alternatively,	a	maleficent	user	may	try	to	harvest	insider	informa-
tion	from	a	breached	company’s	network.	Attackers	may	compro-
mise a company, but not take any of the above actions. Instead, 
they may sell their methods or credentials to another group who 
will	use	them	(Perakslis, 2014)
Scenarios where a cyber attack results in the deaths of individu-
als	or	groups	 (e.g.,	by	corrupting	 the	 firmware	of	a	pacemaker	or	 in-
sulin	 pump)	 can	be	 easily	 imagined	 and	have	been	demonstrated	by	
researchers	(Klonoff, 2015),	but	to	date,	no	such	attack	is	known	to	have	
occurred in the real world. It is possible that that this is because attacks 
against organizations yield greater gain than attacks against individuals.
It is essential therefore to establish best practice methods to 
maintain patient safety and privacy in this new ecosystem of re-
motely managed devices and mass data collection.
7.2.1 | Hacking strategies and methods in mHealth 
technologies
Often times, attackers will not directly compromise the system that 
they are after; they will instead start by compromising a weaker link. 
For example, if the goal is to obtain PHI about a specific patient, they 
may	attempt	to	get	the	patient	(or	a	staff	member)	to	install	a	mali-
cious app, compromising the rest of the phone, including email and 
other credentials. From this point, the attacker is in a better position 
to attack the actual target. The process of chaining exploits to work 
through a system is called pivoting.	Each	pivot	or	“hop”	enables	new	
privileges that bring the hacker closer to desired goals.
The easiest thing to exploit is often a person with phishing cam-
paigns.	A	compromised	email	account	can	be	used	to	reset	passwords	
for other services and to distribute more realistic phishing messages. 
More technical attack pathways are used to compromise the re-
mote-monitoring components of a healthcare system, for example, 
wireless	links	(bluetooth,	wifi,	etc.),	Internet	and	local	network	com-
munications	or	servers	(databases,	web	frontends,	file	servers,	etc.)
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7.2.2 | Recommendations to the manufacturer
It is not possible to create systems that cannot be hacked. However, 
systems/devices should be designed to fail gracefully in conjunction 
with a plan. This enables rapid correction in the event of intrusion.
Business	 decisions	 (e.g.,	 budget,	 timeline)	 should	 not	 override	
security	which	 should	 be	 the	 priority.	 Attempting	 to	 close	 or	 ob-
scure devices/protocols is not a solution, and the so called security 
through obscurity, as a defensive measure, has long been rejected as 
inadequate	(Shanon, 1949).	A	balance	between	usability	and	security	
has to be struck carefully. Securing devices against attackers, while 
keeping them open to clinicians is a difficult task. In mHealth, this 
difficulty can be amplified by the dependence on the patient’s de-
vices	(e.g.,	smartphone)	and	practices,	which	are	outside	the	control	
of	 a	healthcare	 IT	 system.	An	example	of	an	engineering	compro-
mise in implantable cardiac devices is the requirement for important 
wireless communications to only work at very short ranges. These 
communications	could	be	made	more	secure	but	less	usable	(e.g.,	re-
quiring	wires),	or	less	secure	but	more	usable	(e.g.,	using	Bluetooth).
7.2.3 | Recommendations to clinicians and 
administrators
The organization should be designed with security in layers	 (also	
called defense in depth), where each system is protected with more 
than one layer of security. Hence, a breach in one layer will not nec-
essarily result in total compromise. For example, a database may 





innovative solutions include delegating security to a personal base 
station to use a novel radio design that can act as a jammer-cum-
receiver	(Gollakota	et	al.,	2011).
When recommending devices for patients, it is important to con-
sider the potential privacy/security weaknesses compared to alter-
natives, ensure the patient is informed about these tradeoffs, and 
review how the manufacturer has responded to security incidents 
in	the	past	(Saxon, Varma, Epstein, Ganz, & Epstein, 2018).	However,	
the lack of outcome data, combined with the lack of documented 
real-world instances of actual cybersecurity intrusions to these 
devices or to peripheral products that support device connectivity 
(programmer,	 home	 communicator,	 database,	 communication	 pro-
tocols),	 pose	 a	 difficult	 risk–benefit	 assessment	 for	 clinicians	 and	
patients alike.
Regulatory frameworks around cybersecurity are changing rap-
idly	 (Voelker, 2018).	The	FDA	 (as	well	 as	other	 regulatory	agencies	
worldwide)	 now	 includes	 security	 as	 a	 part	 of	 device	 safety/effi-
cacy checks, and we encourage readers to report security issues to 
manufacturers	and	 the	government	 (e.g.,	 through	FDA	Medwatch)	
(Shuren, Patel, & Gottlieb, 2018).
7.2.4 | Recommendations to patients
Clear advice to patients concerning cybersecurity should be fol-
lowed by a formal patient informed consent.
7.3 | Reimbursement
Reimbursement is a powerful driver of adoption of new clinical 
pathways and typically instituted once an intervention has been 
proven	scientifically	valid	and	cost-effective	(Treskes, van der Velde, 
Barendse, & Bruining, 2016).	 This	 process	 has	 only	 just	 started	 in	
mHealth and may be more complex to measure given the wide scope 
of telemedicine.
• Reduced costs
This technology may promote an effective means for early di-
agnosis and treatment of arrhythmias and associated comorbidities, 
leading to benefits of screening, prevention, and early treatment, 
thereby reducing adverse effects related to delayed therapy and 
utilization	of	costly	healthcare	resources	(e.g.,	ER	visits	or	hospital-
izations).	mHealth	may	help	individuals	adhere	to	health	recommen-
dations, empower active participation in lifestyle changes to modify 
cardiovascular risk profile, and promote adherence to medical ther-
apy	 (Feldman et al., 2018).	Together,	 these	may	 reduce	 the	burden	
of chronic disease and associated long-term disability. However, as-
sessment of these longer-term cost advantages is challenging, and 
value will vary according to country and healthcare system.
• Increased costs
Conversely, there are costs associated with administering 
mHealth programs. The widespread availability of smartphones and 
other commercially available mobile devices will generate a signif-
icant amount of inconclusive or false positive findings, which will 
in turn lead to additional testing for validation, thereby increasing 
utilization of healthcare resources. Widespread implementation of 
screening programs would require additional consideration of costs 
related to detection of arrhythmias in currently unscreened pop-
ulations. Healthcare providers will also be required to spend time 
reviewing	 and	 interpreting	 potentially	 voluminous	 results	 (and	 as-
sociated	phone	calls)	prior	to	making	additional	evaluation	and	man-
agement decisions. This requires financial compensation in order to 
maintain a viable practice.
• Remote monitoring of implanted devices
This provides valuable experience. RCTs conducted over many 
years that demonstrated safe and effective replacement of tradi-
tional in-clinic evaluations, and more effective discovery of asymp-
tomatic	 clinical	 events	 (Varma, Epstein, Irimpen, Schweikert, Love, & 
TRUST Investigators, 2010).	 Health-economic	 studies	 like	 EuroEco	
(ICD	 patients)	 showed	 that	 clinic	 time	 needed	 for	 checking	 web-
based information, telephone contacts, and in-clinic discussion when 
required was balanced by fewer planned in-office visits with remote 
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monitoring, resulting in a similar cost for hospitals vs. purely in-office 
follow-up	(Heidbuchel et al., 2014).	From	a	payer	perspective,	there	
was a trend for cost-saving given fewer and shorter hospitalizations, 
seen	also	in	other	trials	 (Crossley et al., 2011, Guedon-Moreau et al., 




digm. This illustrates the complexities in reimbursement.
Currently,	 remote-monitoring	 reimbursement	 (e.g.,	 USA,	
Germany,	France,	UK)	 is	 implemented	 in	a	discrete	way	following	
the	protocols	of	randomized	trials	like	TRUST	or	IN-TIME	(Hindricks 
et al., 2014, Varma, Epstein, Irimpen, Schweikert, Love, & TRUST 
Investigators, 2010, Varma, Michalski, Epstein, & Schweikert, 2010),	
with billing after demonstration of a remote contact, with a maxi-
mum number per year. Given the technological trend toward more 
continuous transmissions, and decision-support server systems 
that alert healthcare providers of potentially relevant information, 
possibly a subscription-based system providing a lump sum per 
year per followed patient may be more effective. This should cover 
costs	of	hardware,	software,	and	other	services	(like	potential	use	
of	third-party	data	monitoring	centers)	and	would	result	in	a	much	
better prospective budgeting for both healthcare insurers and pro-
viders. This scheme may be apt for mobile technology.
It is anticipated that mobile health technology may provide a more 
efficient and cost-effective approach to healthcare delivery that could 
improve clinical workflow and enhance clinical care when integrated 
into	clinical	practice	(Jiang, Ming, & You, 2019).	Linking	this	to	improved	
outcome will be an important driver of reimbursement, for example, 
for	a	process	leading	to	an	arrhythmia	management	decision	(but	not	





reimbursement may extend beyond traditional parties in health care 
and drive novel pathways. Mobile device companies are clearly inter-
ested	in	reimbursement	issues,	evidenced	by	contact	between	Apple	
health executives and insurance companies (Bruining et al., 2014).	
Initiatives	undertaken	in	the	USA	are	described	in	Appendix.
7.4 | Regulatory landscape for mHealth devices
The pace of changes and improvement of digital technology is furi-
ously fast. With the release and spread of the 5G cellular technol-
ogy, this growth will probably be strengthened, and new frontiers 
around data streaming and associated analytics will be crossed. 
Unfortunately, this growth has been slower in the field of digital 
technologies, particularly in the United States. The reasons are prob-
ably linked to the unique relationship between the government and 
its healthcare system. In the United States, mHealth technologies are 
primarily led by private organizations operating under constraints 
linked	 to	 financial	 incentives	 (CMS	 reimbursement	 guidelines),	 pa-
tient	privacy	(Health	Insurance	Portability	and	Accountability	Act),	
and	patient	safety	(Food	and	Drug	Administration,	FDA).	These	con-
straints have become obsolete with the development of the digital 
health technologies and novel mHealth devices, and a new regula-
tory paradigm is being formed.
The	 FDA	 released	 an	 entirely	 new	 section	 under	 the	Medical	
Device	 category	 called	 “Digital	 Health”	 which	 is	 managed	 by	 the	
Center	for	Devices	and	Radiological	Health	(CDRH)	(Shuren, Patel, & 
Gottlieb, 2018, Center for Devices, Radiological Health, 2019).	This	de-
velopment was triggered and supported by the 21st Century Cures 
Act	 signed	 into	 law	on	December	13,	2016.	 It	 is	 designed	 to	help	
accelerate medical product development and bring new innovations 
and	advances	to	patients.	The	FDA	Digital	Health	policy	is	currently	
defined under three main categories: General Wellness, Mobile 
Medical	 Apps	 (MMAs),	 and	 Clinical	 Decision-Support	 Systems.	
mHealth devices are present in these three categories which are de-
fined as follows:
A	wellness	device	is	developed	“for	maintaining	or	encouraging	
a healthy lifestyle and is unrelated to the diagnosis, cure, mitigation, 
prevention,	or	treatment	of	a	disease	or	condition”	(21	CCA	Section	
3060	 (a)(o)(1)(B)).	 The	FDA-regulated	MMAs	on	 the	other	hand	as	
software that is focusing on traditionally regulated health function-
alities	 and	 is	 categorized	 as	 software	 as	 a	medical	 device	 (SaMD).	
The SaMD must be developed under well-defined frameworks in-
volving	specific	software	development	 life	cycles	 (IEC-62304),	 risk	
assessment, reliability demonstration, and safety that includes cy-
bersecurity.	The	clinical	decision-support	(CDS)	systems	may	rely	on	
mHeath devices, or be included in mHeath devices. The definitions 
of	a	CDS	are	provided	in	the	21	CCA,	Section	520	(o)(1)(E).	Briefly,	
they involve the presentation of medical data, recommendations to 
physicians about the prevention, diagnosis, or treatment of a condi-
tion or disease. It is not the intent that the healthcare professional 
primarily relies on this information to make a clinical diagnosis or 
treatment	decisions.	If	wellness	devices	do	not	require	FDA	approval	
to be commercialized both SaMD and CDS do.
The regulatory policies are changing and adapting over time 
to fit the technology development of mHeath devices. Today, the 
time required for approving new technologies is significantly lon-
ger than the pace of change of the mHealth technologies. Hence, 
streamlining the regulatory submission process is of great interest 
to	many	stakeholders.	One	of	the	very	recent	initiatives	in	the	USA	
designed	 to	address	 this	challenge	 is	 the	FDA’s	digital	health	soft-
ware	Precertification	program	(Pre-CERT)	(Lee & Kesselheim, 2018).	
The Pre-CERT is developed to shift the current paradigm of SaMD 
submission. The program is ambitious and proposes to expedite reg-
ulatory review for the companies that can demonstrate a series of 
components that includes process certification, postmarket review, 
and	real-world	evidence	(among	others).	It	 is	expected	that	a	com-
pany	gaining	FDA	Pre-CERT	could	ultimately	eliminate	or	streamline	
their regulatory submission process depending on the risk associ-
ated with their SaMD technologies. Started in 2019, this initiative 
currently involves international companies that are pushing their 
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wellness technologies into the clinical realm. This type of new regu-
latory	framework	will	certainly	help	corporate	America	to	accelerate	
the commercialization of their products, but the Pre-CERT might be 
much more difficult to reach by smaller companies that do not have 
the resources to demonstrate the level of trust, and to implement 
the level of verification and transparency Pre-CERT requires.
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Artificial	 Intelligence	 (AI)	 is	 a	 broad	 term	 that	 describes	 any	 com-
putational programs that normally require human intelligence such 
as image perception, pattern recognition, inference, or prediction 
(www.oed.com; Kagiyama, Shrestha, Farjo, & Sengupta, 2019).	Most	
commonly,	AI	 is	 implemented	using	analytical	methods	of	machine	
learning or deep learning. These methods are well suited for pattern 
classifications, such as images, including ECG.
The	potential	synergy	between	AI	and	mHealth	has	excited	the	
healthcare community since this may enable solutions to improve pa-
tient outcomes and increase efficiency with reduced costs in health 
care	(Davenport & Kalakota, 2019; Marcolino et al., 2018).	Smartphone	
apps and wearable devices generate a huge amount of data that ex-
ceed	the	human	capacity	of	integration	and	interpretation	(Steinhubl,	
Muse,	&	Topol,	2015).	 Biometric	 datasets	of	 astronomical	 propor-
tions may be compiled. This knowledge may be directed to treat an 
individual or understand populations. For instance, 6 billion nights of 
surrogate sleep data reflecting global sleep deprivation may poten-
tially	inform	public	health	initiatives	(Pogue,	2020;	https://aasmo	rg/
fitbi	t-scien	tists	-revea	l-resul	ts-analy	sis-6-billi	on-night	s-sleep	-data).	
Mobile health with Internet connection enables cloud-based pre-
dictive	analytics	from	individual-level	information	(Bumgarner et al., 
2018, Nascimento et al., 2018, Ribeiro, Paixão, et al., 2019).
Cardiology	has	been	an	early	area	of	 investigation	in	AI	due	to	
the abundance of data well suited for classification and prediction 
(Seetharam, Kagiyama, & Sengupta, 2019).	Neural	networks	have	been	
tested, trained, and successfully validated to be at least as accurate, 
if not more, than physicians in diagnosis or classification of 12-lead 
ECGs and recognition of arrhythmias in rhythm strips and ambula-
tory	ECG	recordings	(Hannun et al., 2019, Ribeiro, Ribeiro, et al., 2019, 
Smith et al., 2019). They have also been shown to successfully es-
timate ejection fraction, identify left ventricular dysfunction, and 
even diagnosis diagnose diseases such as hypertrophic cardiomyop-
athy	 from	 the	 echocardiogram	 (Zhang et al., 2018).	More	 recently,	
neural networks have also aided in gathering new dimensions of 
information,	 such	as	 identifying	 left	ventricular	dysfunction	 (Attia, 
Kapa, et al., 2019).	These	methods	have	the	potential	for	a	point-of-
use diagnosis of a wearable sensor or consumer device and without 
delays of requiring clinical conformation, although rigorous safety 
assessments of unsupervised use will be necessary. More recently, 
AI	methods	have	also	been	applied	 to	prediction,	not	 just	 classifi-
cation,	for	example,	using	12-lead	ECG	to	predict	risk	of	AF	from	a	
sinus	rhythm	ECG	(Attia, Noseworthy, et al., 2019b).
Already,	 AI	 has	 been	 embedded	 in	mHealth	 applications,	 such	
as smartwatch and smartphone-connect ECG semi-automated di-
agnosis	of	arrhythmias	 (Bumgarner et al., 2018, Halcox et al., 2017).	
These diagnoses are intended to serve as prediagnostics rather than 
supplanting	a	physician	interpretation.	Application	of	artificial	intel-
ligence techniques to point-of-care ultrasound in the development 
of machine-learning systems may aid in the optimization of acqui-
sition and interpretation of a high volume of images, reduce vari-
ability,	 and	 improve	 diagnostic	 accuracy	 (Chamsi-Pasha, Sengupta, 
& Zoghbi, 2017).	AI-based	prediction	models	have	been	developed	
for	HF	and	AF,	although	sometimes	the	accuracy	of	the	AI-derived	
models seems to be rather limited or not superior than those derived 
from	conventional	methods	 (Awan, Bennamoun, Sohel, Sanfilippo, & 
Dwivedi, 2019, Clifton, Niehaus, Charlton, & Colopy, 2015, Frizzel et al., 
2017, Goto et al., 2019, Safavi et al., 2019, Tripoliti et al., 2019).	mHealth	
specific investigations are few. Results from the LINK-HF study were 
encouraging.	A	cloud-based	analytics	platform	used	a	general	ma-
chine-learning method of similarity-based modeling which models 
the	behavior	of	complex	systems	(e.g.,	aircraft	engines)	to	create	a	
predictive algorithm for HF decompensation, using data streamed 
from a chest patch sensor.
Several limitations should be considered and roadblocks re-
moved	before	AI-based	mHealth	strategies	become	routinely	incor-
porated	 in	 clinical	 practice	 (Kagiyama, Shrestha, Farjo, & Sengupta, 
2019, Powell, 2019, Ribeiro & Oliveira, 2019, Steinhubl, Muse, & Topol, 
2015).	 Studies	 on	 AI	 are	 still	 scarce	 and	 based	 on	 observational	
studies and secondary datasets. Validation in other clinical settings 
and a deeper evaluation of their meaning in every day practice 
are generally lacking. Thus, high-quality evidence that supports 
the adoption of many new technologies is not available. Most al-
gorithms	work	with	the	"black	box"	principle,	without	allowing	the	
user to know the reasons why a diagnosis or recommendation was 
generated, which can be a problem, especially if the algorithms were 
designed for a different environment than the one that the current 
patient	is	inserted	(Ribeiro, Ribeiro, et al., 2019, Weng, 2017).	Issues	
regarding cost-effectiveness, implementation, ethics, privacy, and 
safety are still unsolved.
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mHealth is disruptive at multiple levels of health care but requires sig-
nificant investment in validation, demonstration of clinical utility and 
value. Stakeholders, each with independent concerns and constraints, 
(Table	5)	lack	consensus	or	coordination	with	design,	use	cases,	and	
implementation	 (Figure	7).	Thus,	 formal	 recommendations	 for	 inte-
gration of mHealth into clinical practice cannot be made at this time. 
This is exemplified by the US Preventative Services Task Forces state-
ment	that	“evidence is insufficient	to	initiate	therapy	for	AF	detected	
by	mHealth”—despite	the	fact	that	AF	has	been	an	early	use	case	with	
strong	patient	and	clinician	interest	(Curry et al., 2018).	Thus,	mHealth	
devices are currently nonprescription devices marketed directly to 
consumers to track data without enabling interventions.
Some of the steps needed to standardize mHealth applications 
are outlined below.
1. Validation
• Promote standards and create tools for the comparative assess-
ment of functionality, relative to a medical use device.
Results from different devices applied to the same condition may 
not	match:	for	example,	the	diagnosis	of	AF	by	ECG	or	PPG	based	
systems are made very differently. This has significant implications 
for medical decisions.
2. Identify clinical care pathways
• Screening
a.	 Assess	value	according	to	the	population	addressed
b. Establish a uniform set of criteria for clinical actionability 
(Slotwiner et al., 2019).
Screening should be medically directed and not driven by com-
mercial interests. Caution should be exercised in extrapolating man-
agement strategies learned from cohorts with clinically diagnosed 
AF	(usually	from	healthcare	system	data,	trials	or	inpatient	registries)	
to	 AF	 detected	with	mHealth	 technologies	 (“healthy	 consumers”).	
Data from low-risk populations carry a relatively high risk of false 
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positives, which may generate additional tests with resultant clini-
cal	 risk	 to	patient	 (even	 inducing	anxiety	 rather	 than	reassurance),	
risk from overtreatment, and costs to the payor. There is a risk that 
unless	directed	to	a	higher	 risk	population,	screening	 for	AF	using	
mHealth technologies may fail and follow the trajectory of many 
medical screening programs throughout history.
Key knowledge gap—Identify	 characteristics	 (duration,	 episode	
number/	 density)	 and	 risk	 factors	 that	 justify	 anticoagulation	 for	
mHealth	detected	AF.
• Disease management
a. Identify conditions and schedules for home-based therapeutic 
strategies that may reduce dependency on clinic evaluations 
(as	shown	for	CIEDs)










Eg impact of improved clinical workflow 
and	enhance	clinical	care,	according	to	condition	(Jiang, Ming, & You, 
2019).
Impact on healthcare system and reimbursement
Impact on costs to patient or consumer.
• Public health and Professional society initiatives
TA B L E  5   Conditions, stakeholders and expectations
Applications/ Conditions Opportunities Challenges to resolve
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Excessive focus on data without clinical context
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Patients control the intensity of monitoring and act on pa-
tient-facing data. Frequency of data acquisition is sporadic deter-
mined by, for example, convenience, or following symptoms, or 
recreational. This strategy is likely insensitive for events and rarely 
delivers rapid clinical actionability for life-threatening conditions. 
What is required is as follows:
• Education on which data are clinically actionable in individual’s 
clinical context and
• Tailor monitoring schedule accordingly
• Proof of safety.
In one recent example illustrates an on-demand use. The 
Fibricheck app was utilized by patients to monitor rate and rhythm 
for a week prior to teleconsultations during the COVID-19 pan-
demic to enable remote assessment of the disease state and support 
treatment decisions. This was regulated by a time-limited prescrip-
tion to use the app for a predefined period, avoiding unnecessary 
data-load	and	additional	 follow-up	patients-contacts	 (Pluymaekers 
et al., 2020).
• Patients’ legal right to their medical data to include data collected 
from	nonmedical	(i.e.,	consumer)	products.
5. Manufacturer
mHealth introduces the manufacturer as a party with significant 
responsibilities. mHealth tools largely have been developed as con-
sumer-facing technologies accessible to a broader market through 
retail channels rather than through established medical supply 
channels. This may make business sense for the technology supplier, 
given high community penetration of wearable, smart-technology 
devices	(1	in	10	Americans	(30	million	total)).	However,	a	direct	to	
consumer healthcare delivery bypasses both the clinician, health-





• Facilitate accessibility and affordability
F I G U R E  7   Connectivity and Questions. Multiple levels of cooperation among a variety of stakeholders are needed to capitalize fully on 
the	vast	potential	of	mHealth,	but	many	questions	remain	unanswered.	Healthy	consumers	(increasing)	predominate	among	mhealth	users.	
Only a minority of patients are prescribed these digital tools. Potential health benefits of mHealth may be realized when manufacturer 
participates	with	clinic	for	validation	in	defined	disease	states.	Parties	responsible	for	data	control—and	therby	predictive	analytics—need	to	
be defined. Ultimately, the payor and physician need to be convinced of benefits before digital tools are firmly embedded in clinical practice.
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• Engage with clinicians to engineer devices accord-
ing to clinical needs and partner in validation. This is 
vital, since physician carries ultimate responsibility for 




•	 Identify	parties	 (manufacturer,	hospital,	 third	party)	 responsible	
for cybersecurity, data protection, and liability for mis-diagnosis 
or missed diagnosis
• Define standard of care for clinic response time according to 
condition.
This assumes greater significance as clinical decisions become 
enabled in real time using cloud processing resources linked to en-
hanced	data	transmission	rates	(5G)	and	Internet	of	Things	(IoT)	and	
scalability increases.
•	 Ethical	 and	 societal	 issues	 with	 multiple	 screening	 (Yan et al., 
2020, Turakhia, 2020).
7. Healthcare Delivery
Interconnectedness between individual applications and 
with existing healthcare architectures may reshape the current 
environment.
•	 “Exception-based”	ambulatory	care,	that	 is,	see	patients	as	they	
need to be seen
•	 Centralized	(cloud)	based	processing	to	forward	only	clinically	rel-
evant data to physician/clinic.
•	 Identify	 at-risk	 patients	 early	 (even	 before	 symptoms	 develop)	
and	permit	pre-emptive	care	(Boehmer 2017, Rosier et al., 2016).
•	 Pooled	population	screening—altering	the	paradigm	of	individual	
screening	(Yan et al., 2019, Turakhia, 2020)
• Extend the role of wearables from ambulatory to in-hospital care, 
for example, replace traditional wired monitoring of single param-
eters for individual analysis, to wireless monitoring of multiple 
parameters.
For	example,	a	waterproof	ring	technology	 (Bodimetrics)	was	
used	 for	 multiparametric	 monitoring	 (heart	 rate,	 sleep,	 oxygen	
desaturation	 index,	 steps,	 and	 calories	 burned)	 in	 ICU	 manage-
ment for COVID 19 patients. The ring links to a smartphone or 
centralized hub in hospitals and permits data sharing and coop-
erative	 treatment	 (https://bodim	etrics.com/produ	ct/circu	l-sleep	
-and-fitne	ss-ring/).
• Extend function from monitoring only to intervention
• Enable remote programing of therapeutic implantable devices.
For example, CIEDs, emerging wearable cardioverter-defibril-
lators,	 are	 incorporating	 smartphone	 Bluetooth®	 Low	 Energy	
(BLE)	based	connectivity	 for	 the	 transmission,	display,	and	 inter-
pretation of transmitted data by patients and their clinicians. This 
may permit reprograming of parameters like diagnostic data, de-
tection	 zones,	 clearing	 counters,	 AV	 delays/PVARP	 adjustment,	
upper rate and lower rate adjustments, reprogram amplitude ad-
justments; MRI mode, and enable emergency therapies or disable 
inappropriate therapies due to lead fracture / incessant SVT/ dou-
ble counting.
a. Enable interventional procedures, for example, Tele-Robotic 
ablations models which could improve access to patients liv-
ing in remote areas with highly skilled EPs operating remotely 
(Choi, Oskouian, & Tubbs, 2018, Haidegger, Sándor, & Benyó, 2011, 
Shinoda et al., 2020).
b. Enable precision medicine by incorporation of the wider range 




mHealth application is at different stages of evolution around the 
world. Few of the technologies described are universally approved 
and/or	affordable	in	all	countries.	As	a	result,	this	document	reflects	
largely US perspectives. The experience described may serve to 
guide other members of the international professional bodies en-
dorsing this collaborative statement. The World Health Organization 
envisioned that increasing the capacity to implement and scale up 
cost-effective innovative digital health could play a major role in 
toward achieving universal health coverage and ensuring access 
to quality health services, at the same time recognizing barriers to 
implementation similar to those discussed in this document. Some 
of these can be resolved rapidly, as seen in response to the recent 
SARS-CoV-2	 global	 pandemic	 that	 forced	 a	 need	 for	 contactless	
monitoring	and	thereby	adoption	of	digital	tools	(DHSS, 2020, FDA, 
2020, Varma et al., 2020).	 Regulatory	 bodies	were	 responsive,	 ap-
proving technologies, relaxing rules confining use of telehealth ser-
vices within borders and to certain patient populations, and creating 
a reimbursement structure, illustrating that appropriate solutions 
can be created when necessary.
Demonstration of the clinical utility of mHealth has the poten-
tial to revolutionize how populations interact with health services, 
worldwide.
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APPENDIX 1
In the United States, reimbursement for medical services is 
guided	primarily	by	the	Centers	for	Medicare	&	Medicaid	Services	
(CMS).	 The	 American	 Medical	 Association’s	 Current	 Procedural	
Terminology	(CPT)	Committee	develops	descriptive	codes	for	each	
medical service and assigns a CPT code. Each CPT code is then 
referred to the association’s Relative Value Update Committee 
to	 develop	 a	 recommended	 relative	 value	 unit	 (RVU)	 which	 de-
termines reimbursement. CMS usually accepts the recommenda-
tions	from	the	AMA.	Presently,	the	CPT	Committee	is	developing	
codes to represent the clinical work involved in managing mHealth 
data. These codes will then be evaluated and assigned RVU values. 
If accepted by CMS, these will be included in the Medicare Fee 
Schedule and go into clinical use. This process typically takes 2 
years. Once the codes and services are approved by CMS and pub-




agement code that reimburses primary care practices for non-
face-to-face	 care	 for	 chronic	 care	management	 (CCM)	 payment.	
In November 2018, CMS finalized plans to reimburse healthcare 
providers for certain remote patient monitoring and telehealth 
services. These changes focused on three new CPT codes that 
separate	 remote	 patient	management	 (RPM)	 services	 from	 tele-
health	services.	The	new	CPT	codes	include	#99453,	99454,	and	
99457. The first two codes describe remote monitoring of physi-
ologic parameters, but do not specifically include ECG monitoring. 
The third code provides management services, 20 minutes or more 
of clinical staff/physician/other qualified HCP time in a calendar 
month requiring interactive communication with the patient/
caregiver during the month; however, it is not clear that this code 
could be utilized for ECG monitoring services through mobile de-
vices.	The	pre-existing	CPT	code	93040	(used	for	reporting	on	a	
Rhythm	ECG,	1-3	leads,	without	interpretation	and	report)	would	
not be appropriate for patient initiated mobile device events as 
this would require an order that is triggered by an event followed 
by a separate signed and retrievable report. CMS has also pro-
posed	 establishing	 a	 new	 virtual	 service	 HCPCS	 code,	 GRAS1,	
for	 “Remote	 Evaluation	 of	 Pre-Recorded	 Patient	 Information,”	
which would reimburse for a provider’s asynchronous review of 
“recorded	video	and/or	 images	captured	by	a	patient	 in	order	 to	
evaluate	 the	 patient’s	 condition”	 and	 determine	whether	 or	 not	
an office visit is necessary. This code could be billed separately if 
there was not an E/M visit within the previous seven days. CMS 
finalized	separate	payment	for	CPT	code	99091	(collection	and	in-
terpretation	of	physiologic	data,	e.g.,	ECG,	BP,	glucose	monitoring)	
digitally stored and/or transmitted by the patient and/or caregiver 
to the physician or other qualified HCP, qualified by education, 
training,	licensure/regulation,	requiring	a	minimum	of	30	minutes	
of time. However, there must be a clinically relevant reason for the 
physician to need to review the data each month.
